U.S. patent application number 16/552554 was filed with the patent office on 2020-03-05 for benzimidazole compounds and use thereof for treating alzheimer's disease or huntington's disease.
The applicant listed for this patent is Academia Sinica, National Health Research Institutes. Invention is credited to Chih-Hao Chen, Chiung-Tong Chen, Kai-Fa Huang, Chuan Shih, Hwei-Jiung Wang.
Application Number | 20200071312 16/552554 |
Document ID | / |
Family ID | 69642067 |
Filed Date | 2020-03-05 |
![](/patent/app/20200071312/US20200071312A1-20200305-C00001.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00002.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00003.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00004.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00005.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00006.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00007.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00008.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00009.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00010.png)
![](/patent/app/20200071312/US20200071312A1-20200305-C00011.png)
View All Diagrams
United States Patent
Application |
20200071312 |
Kind Code |
A1 |
Chen; Chih-Hao ; et
al. |
March 5, 2020 |
BENZIMIDAZOLE COMPOUNDS AND USE THEREOF FOR TREATING ALZHEIMER'S
DISEASE OR HUNTINGTON'S DISEASE
Abstract
Benzimidazole compounds of formula (I), shown below, are
disclosed. The compounds are potent human glutaminyl cyclase
inhibitors. Also disclosed is a pharmaceutical composition
containing one of these compounds and a pharmaceutical acceptable
carrier, as well as a method of treating Alzheimer's disease or
Huntington's disease by administering to a subject in need thereof
an effective amount of such a compound. ##STR00001##
Inventors: |
Chen; Chih-Hao; (Taipei
City, TW) ; Shih; Chuan; (Carmel, IN) ; Chen;
Chiung-Tong; (Taipei City, TW) ; Wang;
Hwei-Jiung; (Taipei City, TW) ; Huang; Kai-Fa;
(New Taipei City, TW) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
National Health Research Institutes
Academia Sinica |
Miaoli County
Taipei |
|
TW
TW |
|
|
Family ID: |
69642067 |
Appl. No.: |
16/552554 |
Filed: |
August 27, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62725421 |
Aug 31, 2018 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 409/14 20130101;
A61P 25/28 20180101; C07D 413/14 20130101; C07D 417/14 20130101;
A61K 45/06 20130101; C07D 403/14 20130101 |
International
Class: |
C07D 417/14 20060101
C07D417/14; C07D 403/14 20060101 C07D403/14; A61P 25/28 20060101
A61P025/28; C07D 413/14 20060101 C07D413/14 |
Claims
1. A compound of formula (I): ##STR00349## wherein R.sub.1 is H or
C.sub.1-6 alkyl; R.sub.2 is a moiety containing a phenyl ring fused
to a 5-membered heteroaryl ring, R.sub.2 being linked to N through
the phenyl ring; R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7,
independently, are H, halo, nitro, cyano, amino, OH, CF.sub.3,
C.sub.1-6 alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl, or
heteroaryl that is optionally substituted by one or more
substituents selected from halo, nitro, cyano, amino, OH, CF.sub.3,
--COOH, --COOC.sub.1-6 alkyl, C.sub.1-6 alkoxyl, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
heterocycloalkyl, aryl, and heteroaryl, in which at least one of
R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 is heteroaryl; and
each of C.sub.1-6 alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl,
and heteroaryl, second or third occurrence, is optionally
substituted with halo, nitro, cyano, amino, OH, CF.sub.3, C.sub.1-6
alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; X is
CH.sub.2 or C.dbd.O; and Y is CH.sub.2 or C.dbd.O.
2. The compound of claim 1, wherein Y is CH.sub.2.
3. The compound of claim 2, wherein R.sub.1 is H, X is C.dbd.O, and
R.sub.2 is ##STR00350##
4. The compound of claim 3, wherein R.sub.3, R.sub.4, R.sub.5, and
R.sub.6, independently, are H, CH.sub.3, Cl, or F.
5. The compound of claim 4, wherein R.sub.7 is heteroaryl selected
from the group consisting of ##STR00351## in which R.sub.8 is H,
halo, nitro, cyano, amino, OH, CF.sub.3, --COOH, --COOC.sub.1-6
alkyl, C.sub.1-6 alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl,
or heteroaryl, each of C.sub.1-6 alkoxyl, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
heterocycloalkyl, aryl, and heteroaryl being optionally substituted
with halo, nitro, cyano, amino, OH, CF.sub.3, C.sub.1-6 alkoxyl,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
6. The compound of claim 5, wherein R.sub.8 is H, F, Cl, CH.sub.3,
CF.sub.3, ethyl, n-propyl, ##STR00352##
7. The compound of claim 6, wherein R.sub.7 is selected from the
group consisting of ##STR00353## ##STR00354## ##STR00355##
8. The compound of claim 1, wherein Y is C.dbd.O.
9. The compound of claim 8, wherein R.sub.1 is H, X is C.dbd.O, and
R.sub.2 is ##STR00356##
10. The compound of claim 9, wherein R.sub.3, R.sub.4, R.sub.5, and
R.sub.6, independently, are H, CH.sub.3, Cl, or F.
11. The compound of claim 10, wherein R.sub.7 is heteroaryl
selected from the group consisting of ##STR00357## in which R.sub.8
is H, halo, nitro, cyano, amino, OH, CF.sub.3, --COOH,
--COOC.sub.1-6 alkyl, C.sub.1-6 alkoxyl, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl, each of C.sub.1-6 alkoxyl,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, heterocycloalkyl, aryl, and heteroaryl being optionally
substituted with halo, nitro, cyano, amino, OH, CF.sub.3, C.sub.1-6
alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
12. The compound of claim 11, wherein R.sub.8 is H, F, Cl,
CH.sub.3, CF.sub.3, ethyl, n-propyl, ##STR00358##
13. The compound of claim 12, wherein R.sub.7 is selected from the
group consisting of ##STR00359## ##STR00360## ##STR00361##
14. The compound of claim 1, wherein R.sub.1 is H and X is
C.dbd.O.
15. The compound of claim 1, wherein R.sub.2 is ##STR00362##
16. The compound of claim 1, wherein R.sub.3, R.sub.4, R.sub.5, and
R.sub.6, independently, are H, CH.sub.3, Cl, or F.
17. The compound of claim 1, wherein R.sub.7 is heteroaryl selected
from the group consisting of ##STR00363## in which R.sub.8 is H,
halo, nitro, cyano, amino, OH, CF.sub.3, --COOH, --COOC.sub.1-6
alkyl, C.sub.1-6 alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl,
or heteroaryl, each of C.sub.1-6 alkoxyl, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
heterocycloalkyl, aryl, and heteroaryl being optionally substituted
with halo, nitro, cyano, amino, OH, CF.sub.3, C.sub.1-6 alkoxyl,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
18. The compound of claim 17, wherein R.sub.8 is H, F, C.sub.1,
CH.sub.3, CF.sub.3, ethyl, n-propyl, ##STR00364##
19. The compound of claim 18, wherein R.sub.7 is selected from the
group consisting of ##STR00365## ##STR00366## ##STR00367##
20. The compound of claim 1, wherein the compound is one of the
following compounds: ##STR00368## ##STR00369## ##STR00370##
##STR00371## ##STR00372## ##STR00373## ##STR00374## ##STR00375##
##STR00376## ##STR00377## ##STR00378## ##STR00379## ##STR00380##
##STR00381## ##STR00382## ##STR00383## ##STR00384##
##STR00385##
21. The compound of claim 20, wherein the compound is one of the
following compounds: ##STR00386## ##STR00387##
22. The compound of claim 1, wherein the compound is one of the
following compounds: ##STR00388## ##STR00389## ##STR00390##
##STR00391## ##STR00392## ##STR00393## ##STR00394## ##STR00395##
##STR00396## ##STR00397## ##STR00398## ##STR00399##
##STR00400##
23. A pharmaceutical composition comprising a compound of claim 1
and a pharmaceutically acceptable carrier.
24. A method of treating Alzheimer's disease or Huntington's
disease by administering to a subject in need thereof an effective
amount of a compound of claim 1.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the priority of Provisional
Application No. 62/725,421 filed on Aug. 31, 2018. The content of
this prior application is hereby incorporated by reference in its
entirety.
BACKGROUND
[0002] Alzheimer's disease (AD) and Huntington's disease (HD) are
both incurable degenerative brain diseases.
[0003] More specifically, AD is the most common form of dementia
and HD, on the other hand, causes uncontrolled movements of the
arms, legs, head, face, and upper body. HD also causes a decline in
thinking and reasoning skills, including memory, concentration,
judgement, and ability to plan and organize.
[0004] Both AD and HD are caused by aberrant aggregation of
proteins or peptide. Indeed, AD is triggered by a malfunction of
aggregated mutant .beta.-amyloid peptide (A.beta.) and HD arises
from a toxic function of aggregated mutant huntingtin protein
(HTT).
[0005] Human glutaminyl cyclase (QC) catalyzes cyclization of
N-terminal residues of glutamine or glutamate to form pyroglutamate
(pGlu) on A.beta. and HTT. The pGlu-modified A.beta. and
pGlu-modified HTT thus formed are aggregative, neurotoxic, and
resistant to proteolysis. They can initiate pathological cascades,
resulting in development of AD or HD.
[0006] Inhibition of human QC has been found to diminish
aggregation of both A.beta. and HTT in cultured macrophage cells
and in Drosophila and mouse models. See J. Pharmacol. Exp. Ther.
2017, 362, 119-130; J. Med. Chem. 2017, 60, 2573-2590; Nat. Med.
2008, 14(10), 1106-1111; and Nat. Chem. Bio. 2015, 11, 347-354.
[0007] As such, human QC is an emerging drug target for the
treatment of AD or HD.
[0008] Currently, only a few drug candidates that inhibit QC are in
clinical trials for treating AD or HD. There is a need to develop
new QC inhibitors.
[0009] Earlier studies have shown that QC is a zinc-dependent
enzyme. As such, compounds capable of chelating zinc at active
sites of QC, e.g., benzimidazole compounds, are potential QC
inhibitors.
SUMMARY
[0010] Certain benzimidazole compounds have been found to be QC
inhibitors. Unexpectedly, the compounds demonstrate high potency in
inhibiting QC and, as such, can be used for treating AD or HD.
[0011] In one aspect, this invention relates to the benzimidazole
compounds of formula (I) below:
##STR00002##
[0012] X and Y, independently, are CH.sub.2 or C.dbd.O; R.sub.1 is
H or C.sub.1-6 alkyl; R.sub.2 is a moiety containing a phenyl ring
fused to a 5-membered heteroaryl ring (e.g.,
##STR00003##
being linked to N through the phenyl ring; R.sub.3, R.sub.4,
R.sub.5, R.sub.6, and R.sub.7, independently, are H, halo (e.g., F,
Cl, Br, or I), nitro, cyano, amino, OH, CF.sub.3, C.sub.1-6
alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl that
is optionally substituted by one or more substituents selected from
halo (e.g., F, Cl, Br, or I), nitro, cyano, amino, OH, CF.sub.3,
--COOH, --COOC.sub.1-6 alkyl, C.sub.1-6 alkoxyl, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
heterocycloalkyl, aryl, and heteroaryl, wherein at least one of
R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 is heteroaryl and
wherein each of C.sub.1-6 alkoxyl, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
heterocycloalkyl, aryl, and heteroaryl, second or third occurrence,
is optionally substituted with halo (e.g., F, Cl, Br, or I), nitro,
cyano, amino, OH, CF.sub.3, C.sub.1-6 alkoxyl, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl.
[0013] Examples of heteroaryl assigned to R.sub.7 include
##STR00004##
in which R.sub.8 is H, halo (e.g., F, Cl, Br, or I), nitro, cyano,
amino, OH, CF.sub.3, --COOH, --COOC.sub.1-6 alkyl, C.sub.1-6
alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl,
C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each
of C.sub.1-6 alkoxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-10 cycloalkyl, heterocycloalkyl, aryl, and
heteroaryl being optionally substituted with halo (e.g., F, Cl, Br,
or I), nitro, cyano, amino, OH, CF.sub.3, C.sub.1-6 alkoxyl,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-10
cycloalkyl, heterocycloalkyl, aryl, or heteroaryl.
[0014] Among specific assignments to R.sub.7 are
##STR00005## ##STR00006## ##STR00007##
[0015] Among specific assignments to R.sub.8 are H, F, Cl,
CH.sub.3, CF.sub.3, ethyl, n-propyl,
##STR00008##
[0016] The above-described compounds can be classified into two
subsets. In one subset, Y is CH.sub.2 and, in the other subset, Y
is C.dbd.O. Preferred compounds in each subset feature that R.sub.1
is H; X is C.dbd.O; R.sub.2 is
##STR00009##
R.sub.3, R.sub.4, R.sub.5, and R.sub.6, independently, are H or F;
R.sub.7 is
##STR00010##
in which the assignments to R.sub.8 are set forth in the preceding
paragraph. In particularly preferred compounds, the assignments to
R.sub.7 are also set forth in the preceding paragraph.
[0017] The term "alkyl" herein refers to a saturated, linear, or
branched hydrocarbon moiety, e.g., --CH.sub.3 or
--CH(CH.sub.3).sub.2. The term "alkoxy" refers to an --O(C.sub.1-6
alkyl) radical, e.g., --OCH.sub.3 and --OCH(CH.sub.3).sub.2. The
term "alkenyl" refers to a linear or branched hydrocarbon moiety
that contains at least one double bond, e.g.,
--CH.dbd.CH--CH.sub.3. The term "alkynyl" refers to a linear or
branched hydrocarbon moiety that contains at least one triple bond,
e.g., --C.ident.C--CH.sub.3. The term "cycloalkyl" refers to a
saturated mono-, di-, or tri-cyclic hydrocarbon moiety, e.g.,
cyclohexyl. The term "heterocycloalkyl" refers to a saturated
mono-, di-, or tri-cyclic moiety having at least one ring
heteroatom (e.g., N, O, and S), e.g., 4-tetrahydropyranyl. The term
"aryl" refers to a hydrocarbon moiety having one or more aromatic
rings. Examples of aryl include phenyl, phenylene, naphthyl,
naphthylene, pyrenyl, anthryl, and phenanthryl. The term
"heteroaryl" refers to a moiety having one or more aromatic rings
that contain at least one heteroatom (e.g., N, O, and S). Examples
of heteroaryl include furyl, furylene, fluorenyl, pyrrolyl,
thienyl, oxazolyl, imidazolyl, thiazolyl, pyridyl, pyrimidinyl,
quinazolinyl, quinolyl, isoquinolyl, and indolyl. The term "amino"
refers to a radical of --NH.sub.2, --NH(C.sub.1-6 alkyl), or
--N(C.sub.1-6 alkyl).sub.2, e.g., --NHCH.sub.3 and
--NHCH(CH.sub.3).sub.2.
[0018] Alkoxy, Alkyl, alkenyl, alkynyl, cycloalkyl,
heterocycloalkyl, aryl, and heteroaryl mentioned herein include
both substituted and unsubstituted moieties, unless specified
otherwise. Substituents on alkoxy, alkyl, alkenyl, alkynyl,
cycloalkyl, heterocycloalkyl, aryl, and heteroaryl include, but are
not limited to, halo, nitro, cyano, amino, OH, CF.sub.3, --COOH,
--COOC.sub.1-6 alkyl, C.sub.1-6 alkoxyl, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-10 cycloalkyl,
heterocycloalkyl, aryl, or heteroaryl.
[0019] The compounds described above include the compounds
themselves, as well as their salts, prodrugs, stereoisomers, and
tautomers, if applicable. A salt, for example, can be formed
between an anion and a positively charged group (e.g., amino) on a
compound of formula (I). Suitable anions include chloride, bromide,
iodide, sulfate, nitrate, phosphate, citrate, methanesulfonate,
trifluoroacetate, acetate, malate, tosylate, tartrate, fumurate,
glutamate, glucuronate, lactate, glutarate, and maleate. Likewise,
a salt can also be formed between a cation and a negatively charged
group (e.g., carboxylate) on a compound of formula (I). Suitable
cations include sodium ion, potassium ion, magnesium ion, calcium
ion, and an ammonium cation such as tetramethylammonium ion. The
compounds also include those salts containing quaternary nitrogen
atoms. Examples of prodrugs include esters and other
pharmaceutically acceptable derivatives, which, upon administration
to a subject, are capable of providing active compounds.
Stereoisomers of the compounds of formula (I) can include cis and
trans isomers, optical isomers such as (R) and (S) enantiomers,
diastereomers, geometric isomers, rotational isomers, atropisomers,
conformational isomers, and mixtures thereof. Tautomers of the
compounds include those exhibiting more than one type of
isomerism.
[0020] In another aspect, this invention relates to a
pharmaceutical composition containing a compound of formula (I) and
a pharmaceutical acceptable carrier.
[0021] The carrier in the pharmaceutical composition must be
"acceptable" in the sense that it is compatible with the active
ingredient of the composition (and preferably, capable of
stabilizing the active ingredient) and not deleterious to the
subject to be treated. Examples of carriers include colloidal
silicon oxide, magnesium stearate, cellulose, sodium lauryl
sulfate, and D&C Yellow 10.
[0022] Also within the scope of this invention is a method of
treating AD or HD. The method includes administering to a subject
in need thereof an effective amount of a compound of formula
(I).
[0023] The term "treating" refers to application or administration
of the compound or its salt, prodrug, stereoisomer, or tautomer to
a subject with the purpose to confer a therapeutic effect, i.e., to
cure, relieve, alter, affect, ameliorate, or prevent AD or HD, the
symptom of AD or HD, or the predisposition toward AD or HD.
[0024] "An effective amount" is the amount of the compound or its
salt, prodrug, stereoisomer, or tautomer, which is required to
confer the desired effect on the subject. Effective amounts vary,
as recognized by those skilled in the art, depending on route of
administration, excipient usage, and the possibility of co-usage
with other therapeutic treatments such as use of other active
agents.
[0025] A composition having a compound of formula (I) or its salt,
prodrug, stereoisomer, or tautomer can be administered parenterally
or orally. The term "parenteral" as used herein refers to
subcutaneous, intracutaneous, intravenous, intraperitoneal,
intramuscular, intraarticular, intraarterial, intrasynovial,
intrasternal, intrathecal, intralesional, or intracranial
injection, as well as any suitable infusion technique.
[0026] A composition for oral administration can be any orally
acceptable dosage form, e.g., capsules, tablets, emulsions and
aqueous suspensions, dispersions, and solutions. In the case of
tablets, commonly used carriers include, among others, lactose and
corn starch. Lubricating agents, such as magnesium stearate, are
also typically added. For oral administration in a capsule form,
useful diluents include lactose and dried corn starch. When aqueous
suspensions or emulsions are administered orally, the active
ingredient can be suspended or dissolved in an oily phase combined
with an emulsifying or suspending agent. If desired, a sweetening,
flavoring, or coloring agent can be added.
[0027] The details of one or more embodiments of the invention are
set forth in the description below. Other features, objects, and
advantages of the invention will be apparent from the description
and from the claims.
DETAILED DESCRIPTION
[0028] Disclosed in detail hereinafter are the benzimidazole
compounds of formula (I) shown above.
[0029] Compounds of this invention that have chiral centers may
exist as stereoisomers. Stereoisomers of the compounds of formula
(I) can include cis and trans isomers, optical isomers such as (R)
and (S) enantiomers, diastereomers, geometric isomers, rotational
isomers, atropisomers, conformational isomers, and tautomers of the
compounds, including compounds exhibiting more than one type of
isomerism; and mixtures thereof (such as racemates and
diastereomers). All such isomeric forms are contemplated. In
addition, the compounds of formula (I) in the present invention may
exhibit the phenomena of tautomerism.
[0030] Of note, the compounds of formula (I) can have an
enantiomeric excess of 90% or higher (e.g., .gtoreq.95% and
.gtoreq.99%).
[0031] 117 exemplary compounds of formula (I) are shown in Table 1
below:
TABLE-US-00001 TABLE 1 ##STR00011## 1 ##STR00012## 2 ##STR00013## 3
##STR00014## 4 ##STR00015## 5 ##STR00016## 6 ##STR00017## 7
##STR00018## 8 ##STR00019## 9 ##STR00020## 10 ##STR00021## 11
##STR00022## 12 ##STR00023## 13 ##STR00024## 14 ##STR00025## 15
##STR00026## 16 ##STR00027## 17 ##STR00028## 18 ##STR00029## 19
##STR00030## 20 ##STR00031## 21 ##STR00032## 22 ##STR00033## 23
##STR00034## 24 ##STR00035## 25 ##STR00036## 26 ##STR00037## 27
##STR00038## 28 ##STR00039## 29 ##STR00040## 30 ##STR00041## 31
##STR00042## 32 ##STR00043## 33 ##STR00044## 34 ##STR00045## 35
##STR00046## 36 ##STR00047## 37 ##STR00048## 38 ##STR00049## 39
##STR00050## 40 ##STR00051## 41 ##STR00052## 42 ##STR00053## 43
##STR00054## 44 ##STR00055## 45 ##STR00056## 46 ##STR00057## 47
##STR00058## 48 ##STR00059## 49 ##STR00060## 50 ##STR00061## 51
##STR00062## 52 ##STR00063## 53 ##STR00064## 54 ##STR00065## 55
##STR00066## 56 ##STR00067## 57 ##STR00068## 58 ##STR00069## 59
##STR00070## 60 ##STR00071## 61 ##STR00072## 62 ##STR00073## 63
##STR00074## 64 ##STR00075## 65 ##STR00076## 66 ##STR00077## 67
##STR00078## 68 ##STR00079## 69 ##STR00080## 70 ##STR00081## 71
##STR00082## 72 ##STR00083## 73 ##STR00084## 74 ##STR00085## 75
##STR00086## 76 ##STR00087## 77 ##STR00088## 78 ##STR00089## 79
##STR00090## 80 ##STR00091## 81 ##STR00092## 82 ##STR00093## 83
##STR00094## 84 ##STR00095## 85 ##STR00096## 86 ##STR00097## 87
##STR00098## 88 ##STR00099## 89 ##STR00100## 90 ##STR00101## 91
##STR00102## 92 ##STR00103## 93 ##STR00104## 94 ##STR00105## 95
##STR00106## 96 ##STR00107## 97 ##STR00108## 98 ##STR00109## 99
##STR00110## 100 ##STR00111## 101 ##STR00112## 102 ##STR00113## 103
##STR00114## 104 ##STR00115## 105 ##STR00116## 106 ##STR00117## 107
##STR00118## 108 ##STR00119## 109 ##STR00120## 110 ##STR00121## 111
##STR00122## 112 ##STR00123## 113 ##STR00124## 114 ##STR00125## 115
##STR00126## 116 ##STR00127## 117
[0032] Among the 117 compounds listed above, Compounds 9 and 10 are
the two enantiomers of Compound 8; Compounds 33 and 34 are the two
enantiomers of Compound 13; Compounds 35 and 36 are the two
enantiomers of Compound 16; Compounds 53 and 54 are the two
enantiomers of Compound 25; and Compounds 55 and 56 are the two
enantiomers of Compound 28.
[0033] Compounds 9, 34, 36, 54, and 56 are preferred.
[0034] Methods for synthesizing the compounds of formula (I) are
well known in the field. Note that the procedures for preparing as
many as 67 compounds, i.e., Compounds 1-67, are set forth in
EXAMPLE 1 below.
[0035] The compounds thus prepared can be initially screened using
in vitro assays for their potency in inhibiting the activity of
glutaminyl cyclase (QC). The in vitro assays are set forth in
EXAMPLE 2 below. Further, the prepared compounds can be
subsequently evaluated using in vivo assays. The in vivo assays are
set forth in EXAMPLE 3 below. The selected compounds can be further
tested to verify their efficacy in treating AD or HD. Based on the
results, appropriate dosage ranges and administration routes can be
investigated and determined.
[0036] All reagents and solvents were purchased from commercial
suppliers and used without further purification unless otherwise
noted. All anhydrous reactions were performed under a nitrogen
atmosphere using dry solvents. All reactions were monitored by thin
layer chromatography using Merck Silica gel 60 F.sub.254
glass-backed plate. Column chromatography was performed by Merck
silica gel 60 (0.040-0.063 mm, 230-400 mesh). Purity of the final
compounds was determined on a Hitachi 2000 series HPLC system with
a reverse phase Cis column (Agilent ZORBAX Eclipse XDB-C18 5 .mu.m,
4.6 mm.times.150 mm), operating at 25.degree. C. Mobile phase A was
acetonitrile. Mobile phase B was 10 mM NH.sub.4OAc aqueous solution
containing 0.1% formic acid. The gradient system started from A/B
(10%/90%) at 0 min to A/B (90%/10%) at 45 min. The flow rate of the
mobile phase was 0.5 mL/min, and the injection volume of the sample
was 5 .mu.L. Peaks were detected at 254 nm. The purity of all
tested compounds is >95%. LC/MS data were measured on an Agilent
MSD-1100 ESI-MS/MS System. All tested compounds were detected at UV
254 nm unless otherwise stated. .sup.1H NMR spectra were measured
by Varian Mercury-300 and Varian Mercury-400 spectrometers, and the
chemical shifts (6) were reported in parts per million (ppm)
relative to the resonance of the solvent peak. Multiplicities are
reported with the following abbreviations: s (singlet), d
(doublet), t (triplet), q (quartet), quin (quintet), m (multiplet),
or br (broad).
[0037] Without further elaboration, it is believed that one skilled
in the art can, based on the above description, utilize the present
invention to its fullest extent. The specific embodiments described
in EXAMPLES 1-3 below are, therefore, to be construed as merely
illustrative, and not limitative of the remainder of the disclosure
in any way whatsoever. All publications cited herein are
incorporated by reference.
Example 1: Preparation and Characterization of Compounds
[0038] Compounds 1-67 were prepared by Synthetic Methods 1-18
respectively shown in Schemes 1-18 below.
Synthetic Method 1
[0039] Compounds 1-4, each having a 1,3-thiazol-2-yl ring, were
prepared according to the synthetic procedures shown in Scheme 1
below. (4-Formylphenyl)boronic acid 118 was coupled with
2-bromothiazole derivatives 119a-d under a Suzuki-coupling
condition to afford 4-(1,3-thiazol-2-yl)benzaldehyde derivatives
120a-d. The core structure of imidazolidinone ring was built in the
following three steps. TMSCN was added to a solution of
benzaldehydes 120a-d and 1H-benzimidazol-5-amine 121 in acetic
acid. The reaction mixture was stirred at room temperature for 2
hours and then worked up to yield amino acetonitriles 122a-d, which
were hydrogenated using Raney Nickel catalyst in acetic acid at
5-10.degree. C. to afford diamines 123a-d. In the final step,
1,1'-carbonyldiimidazole (CDI) was added to a solution of diamines
123a-d in THF and then stirred at 75.degree. C. for 18 hours.
Compounds 1-4 were obtained after purification by column
chromatography.
##STR00128##
Synthetic Method 2
[0040] 4-(2-Cyclopropyl-1,3thiazol-4-yl)benzaldehyde 127, a
precursor, was synthesized under two different Suzuki-coupling
conditions shown in Scheme 2 below. 2,4-Dibromo-1,3-thiazole 124, a
starting material, was selectively coupled at 2-position with
cyclopropylboronic acid 125 using Pd(OAc).sub.2 as a catalyst. The
resultant product 126 was coupled at 4-position with
(4-formylphenyl)boronic acid 118 using Pd(dppf)Cl.sub.2 as a
catalyst to afford precursor 127 having a 1,3-thiazol-4-yl ring.
This precursor was then applied to the procedures shown in
Synthetic Method 1 for forming imidazolidinone to obtain the final
compound (Compound 5).
##STR00129##
Synthetic Method 3
[0041] Compounds 6-8, each having a 3-thiazol-5-yl ring, were
prepared in eight steps as shown in Scheme 3 below. Commercially
available starting material 4-(bromoacetyl)-benzonitrile 130 was
transformed into 4-(aminoacetyl)benzonitrile hydrochloride 131
after a substitution reaction using HMTA followed by refluxing in a
solution of hydrochloride acid in ethanol. Compound 131 was then
acetylated with variable anhydrides 132a-c to obtain amides 133a-c,
which were subsequently treated with the Lawesson's reagent in THF
or toluene under reflux to afford (1,3-thiazol-5-yl)benzonitrile
analogs 134a-c. The benzonitrile analogs 134a-c were reduced by
DIBAL-H to form benzaldehyde precursors 135a-c. These precursors
were then applied to the procedures shown in Synthetic Method 1 for
forming imidazolidinone to obtain Compounds 6-8.
##STR00130## ##STR00131##
Synthetic Method 4
[0042] Compounds 11 and 29-32, each having a thiophen-2-yl ring,
were prepared by the synthetic procedures shown in Scheme 4 below.
4-Bromobenzaldehydes 138a-d were each coupled with 2-substituted
thiophene 139a or 139b under a Suzuki-coupling condition to afford
benzaldehyde precursors 140a-e. These precursors were then applied
to the procedures shown in Synthetic Method 1 for forming
imidazolidinone to obtain Compounds 11 and 29-32.
##STR00132## ##STR00133##
Synthetic Method 5
[0043] Compound 12, having a thiophen-2-yl ring, was prepared by
the synthetic procedures shown in Scheme 5. 4-Acetyl benzonitrile
143 was .alpha.-methylenated using FeCl.sub.3.6H.sub.2O and
K.sub.2S.sub.2O.sub.8 in dimethylacetamide (DMA). The resultant
.alpha.-methylene product 144 reacted with cyclopropanecarbaldehyde
under a Stetter condition to form 1,4-dicarbonyl compound 146. This
dicarbonyl compound was then treated with the Lawesson's reagent
under refluxing in toluene to afford
4-(5-cyclopropylthiophen-2-yl)benzonitrile 147, which was reduced
by DABAL-H to form benzaldehyde precursor 148. This precursor was
then applied to the procedures shown in Synthetic Method 1 for
forming imidazolidinone to obtain Compound 12.
##STR00134## ##STR00135##
Synthetic Method 6
[0044] Compounds 13 and 22-24, each having a thiophen-2-yl ring,
were prepared by the synthetic procedures shown in Scheme 6.
4-Bromobenzaldehydes 138a-d were each coupled with thiophene under
two different Suzuki-coupling conditions to form
4-(thiophen-2-yl)-benzaldehydes 152a-d. The benzaldehydes were
iodinated by N-iodosuccinimide (NIS) to produce iodinated products
153a-d, which were trifluoromethylated using methyl
difluoro-(fluoro-sulfonyl)acetate 154 and copper iodide to afford
precursors 155a-d. These precursors were then applied to the
procedures shown in Synthetic Method 1 for forming imidazolidinone
to obtain Compounds 13 and 22-24.
##STR00136## ##STR00137##
Synthetic Method 7
[0045] Compounds 14-16 and 25-28, each having a thiophen-3-yl ring,
were prepared by the synthetic procedures shown in Scheme 7.
Various (4-formylphenyl)boronic acids were coupled with
3-bromothiophene derivatives 158a-c under a Suzuki-Miyaura coupling
condition. The resultant products 159a-g were then applied to the
procedures shown in Synthetic Method 1 for forming imidazolidinone
to obtain Compounds 14-16 and 25-28.
##STR00138##
Synthetic Method 8
[0046] Compound 17, having a thiophen-3-yl ring, was prepared by
the synthetic procedures shown in Scheme 8 below. Starting material
159a was selectively brominated by bromine or NBS in acetic acid to
afford 2-brominated thiophene product 162, which was coupled with
cyclopropyl-boronic acid under a Suzuki-coupling condition to form
4-(2-cyclopropyl-thiophen-3-yl)benzaldehyde 163. This benzaldehyde
was then applied to the procedures shown in Synthetic Method 1 for
forming imidazolidinone to obtain Compound 17.
##STR00139## ##STR00140##
Synthetic Method 9
[0047] Compound 18, having a 1,2,4-oxadiazol-3-yl ring, was
prepared by the synthetic procedures shown in Scheme 9.
4-Formylbenzonitrile 166, a starting material, was protected by
monoethyleneglycol (MEG) to form acetal 167, which reacted with
hydroxylamine hydrochloride to afford amidoxime 168. The amidoxime
was acetylated by cyclopropanecarbonyl chloride and then refluxed
in toluene to form 1,2,4-oxadiazole 170, which was deprotected
under acidic condition. The resultant product 171 reacted with
TMSCN and 1H-benzimidazol-5-amine 121 in acetic acid at room
temperature for 2 hours and was then worked up to yield amino
acetonitrile 172. The amino acetonitrile was hydrogenated with a
Pd/C catalyst in acetic acid at room temperature overnight to
afford diamine 173. In the final step, 1,1'-carbonyldiimidazole was
added to a solution of diamine 173 in THF and then stirred at
75.degree. C. for 18 hours. Compound 18 was finally obtained after
purification by column chromatography.
##STR00141## ##STR00142##
Synthetic Method 10
[0048] Compound 19, having a 1,2-oxazol-3-yl ring, was prepared by
the synthetic procedures shown in Scheme 10.
Cyclopropanecarbaldehyde 174, the starting material, reacted with
hydroxylamine hydrochloride to afford oxime 175, which was treated
first with N-chlorosuccinimide (NCS) and then with
4-ethynylbenzaldehyde 176 in DMF at room temperature to form
1,2-oxazole precursor 177. This precursor was then applied to the
procedures shown in Synthetic Method 9 for forming imidazolidinone
to obtain Compound 19.
##STR00143##
Synthetic Method 11
[0049] Compounds 20 and 21, each having a 2H-tetrazol-5-yl ring,
were prepared by the synthetic procedures shown in Scheme 11.
4-Formylbenzonitrile 166, the starting material, reacted with
sodium azide and ammonium chloride in DMF under refluxing to form
tetrazole compound 180, which was substituted by variable alkyl
halides to afford precursors 181a-b. These precursors were then
applied to the procedures shown in Synthetic Method 9 for forming
imidazolidinone to obtain Compounds 20 and 21.
##STR00144##
Synthetic Method 12
[0050] Compound 37, having a 1,3-thiazol-2-yl ring, was prepared by
the synthetic procedures shown in Scheme 12.
(4-Acetylphenyl)boronic acid 184 was coupled with
2-bromo-4-(trifluoromethyl)-1,3-thiazole 119d under a
Suzuki-coupling condition. The resultant product 185 was oxidized
by selenium dioxide to afford glyoxal 186. The glyoxal was mixed
with benzimidazolylurea 187 in HCl/AcOH (1/40 v/v) and then
refluxed overnight. After removing the solvents under reduced
pressure, the residue was treated with excess ammonia solution in
methanol for several hours. The crude product was purified by
column chromatography to yield Compound 37.
##STR00145##
Synthetic Method 13
[0051] Compound 38, having a 1,3-thiazol-4-yl ring, was prepared by
the synthetic procedures shown in Scheme 13.
4-Bromo-2-cyclopropyl-1,3-thiazole 126, an intermediate prepared
following Synthetic Method 2, was coupled with
(4-acetylphenyl)boronic acid 184 under a Suzuki-coupling condition.
The resultant coupling product 188 was oxidized by selenium dioxide
to glyoxal 189. Compound 38 was formed from glyoxal 189 and
benzimidazolylurea 187 via a cycloaddition reaction. The procedures
were the same those shown in Synthetic Method 12.
##STR00146##
Synthetic Method 14
[0052] Compounds 39 and 40, each having a 1,3-thiazol-5-yl ring,
were prepared by the synthetic procedures shown in Scheme 14.
1,3-Thiazol-5-ylbenzonitriles 134b-c, intermediates prepared
following Synthetic Method 3, were acetylated by methylmagnesium
bromide. The resultant acetyl products 190b-c were oxidized by
selenium dioxide to glyoxals 191b-c. Compounds 39 and 40 were
formed from glyoxals 191b-c and benzimidazolylurea 187 via a
cycloaddition reaction. The procedures were the same as those shown
in Synthetic Method 12.
##STR00147##
Synthetic Method 15
[0053] Compounds 41-52, each having a 2H-tetrazol-5-yl ring, were
prepared by the synthetic procedures shown in Scheme 15. Starting
material 143 reacted with sodium azide and ammonium chloride under
refluxing in DMF to form tetrazole 192, which was substituted with
variable alkyl halides to give precursors 193a-l. These precursors
were then applied to the procedures shown in Synthetic Method 12
for forming hydantoin to yield Compounds 41-52.
##STR00148## ##STR00149##
Synthetic Method 16
[0054] Compound 57 having a 1,3-thiazol-5-yl ring was prepared by
the synthetic procedures shown in the Scheme 16. Starting material
131 was acetylated with adamantane-1-carbonyl chloride 195 to
obtain amide 196. Subsequently, the amide 196 was mixed with the
Lawesson's reagent under reflux in THF to afford
(1,3-thiazol-5-yl)-benzonitrile 197, which was reduced by DIBAL-H
to form benzaldehyde 198. The benzaldehyde 198 was then applied to
the procedures shown in Synthetic Method 1 for forming
imidazolidinone to obtain Compound 57.
##STR00150## ##STR00151##
Synthetic Method 17
[0055] Compounds 58-65 each having a thiophen-3-yl ring were
prepared by the synthetic procedures shown in Scheme 17.
2,3-Difluoro-4-formylphenylboronic acid 118g was coupled with
3-bromothiophene derivatives 158a-b and 158d-i under a
Suzuki-Miyaura coupling condition. The resulting products 201a-h
were then applied to the procedures shown in Synthetic Method 1 for
forming imidazolidinone to obtain Compound 58-65.
##STR00152## ##STR00153##
Synthetic Method 18
[0056] Compound 66 was prepared through hydrolysis reaction of
compound 64 in a solution of potassium hydroxide in methanol shown
in Scheme 18. Compound 67 was prepared through reduction of
compound 64 by LAH in dry THF also shown in this scheme.
##STR00154##
[0057] Below are the detailed procedures of preparing Compounds
1-67 following Synthetic Methods 1-18 set forth above and the
analytical data of the intermediates and the final products
generated in these procedures.
4-(1,3-thiazol-2-yl)benzaldehyde (Compound 120a)
##STR00155##
[0059] The (4-formylphenyl)boronic acid 118 (0.30 g, 2.0 mmol),
2-bromo-1,3-thiazole 119a (0.33 g, 2.0 mmol),
Pd(PPh.sub.3).sub.4(0.12 g, 0.1 mmol), aqueous solution of
potassium carbonate (0.4 M, 5 mL), ethanol (5 mL) and toluene (2
mL) were added to a 50 mL flask under nitrogen. The reaction
mixture was stirred at 115.degree. C. for 24 hours and then cooled
to room temperature. After removing the solvent, the crude residue
was purified by column chromatography on silica gel using EA/hexane
(1/5) as eluent. The product 120a was obtained as a white solid at
a yield of 95%.
4-(4-methyl-1,3-thiazol-2-yl)benzaldehyde (Compound 120b)
##STR00156##
[0061] The 4-(4-methyl-1,3-thiazol-2-yl)benzaldehyde 120b was
prepared from the Suzuki-coupling of (4-formylphenyl)boronic acid
118 and 2-bromo-4-methyl-1,3-thiazole 119b. The procedures were the
same as the synthesis of Compound 120a. The product 120b was
obtained as a white solid at a yield of 90%.
4-(4-cyclopropyl-1,3-thiazol-2-yl)benzaldehyde (Compound 120c)
##STR00157##
[0063] The 4-(4-cyclopropyl-1,3-thiazol-2-yl)benzaldehyde 120c was
prepared from the Suzuki-coupling of (4-formylphenyl)boronic acid
118 and 2-bromo-4-cyclopropyl-1,3-thiazole 119c. The procedures
were the same as the synthesis of Compound 120a. The product 120c
was obtained as a white solid at a yield of 92%.
4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]benzaldehyde (Compound
120d)
##STR00158##
[0065] The 4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]benzaldehyde
120d was prepared from the Suzuki-coupling of
(4-formylphenyl)boronic acid 118 and
2-bromo-4-(trifluoromethyl)-1,3-thiazole 119d. The procedures were
the same as the synthesis of Compound 120a. The product 120d was
obtained as a white solid at a yield of 90%.
(1H-benzimidazol-5-ylamino)[4-(1,3-thiazol-2-yl)phenyl]acetonitrile
(Compound 122a)
##STR00159##
[0067] To the solution of 1H-benzimidazol-5-amine 121 (0.68 g, 5.11
mmol) in acetic acid (20 mL), the Compound 120a (1.06 g, 5.62 mmol)
was added and stirred at room temperature for 20 minutes. TMSCN (1
mL) was added dropwise to the reaction mixture and continuously
stirred for 2 hours. After reaction completing, the reaction
mixture was concentrated under reduced pressure to yield a viscous
liquid. The viscous liquid was diluted with ethyl acetate (10 mL)
and water. The diluted solution was adjusted to the pH 6-7 with
ammonia at an ice-bath. The neutralized solution was extracted with
ethyl acetate (20 mL.times.4), dried over sodium sulfate, filtered
and concentrated under reduced pressure to yield a viscous
dark-yellow solid. The solid was dissolved in ethyl acetate (15 mL)
and brine (15 mL). The mixture was stirred at room temperature for
2 minutes to form the pale-yellow precipitates. The pale-yellow
precipitates was filtered and washed with water. The filtrate was
dried over sodium sulfate and concentrated under reduced pressure
to obtain the pale-yellow solid. Those pale-yellow solids were
combined as the desired product 122a at a yield of 96%.
(1H-benzimidazol-5-ylamino)
[4-(4-methyl-1,3-thiazol-2-yl)phenyl]acetonitrile (Compound
122b)
##STR00160##
[0069] The
(1H-benzimidazol-5-ylamino)[4-(4-methyl-1,3-thiazol-2-yl)phenyl-
]acetonitrile 122b was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 120b. The
procedures were the same as the synthesis of Compound 122a. The
product 122b was obtained as a pale-yellow solid at a yield of
97%.
(1H-benzimidazol-5-ylamino)
[4-(4-cyclopropyl-1,3-thiazol-2-yl)phenyl]acetonitrile (Compound
122c)
##STR00161##
[0071] The
(1H-benzimidazol-5-ylamino)[4-(4-cyclopropyl-1,3-thiazol-2-yl)p-
henyl]acetonitrile 122c was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 120c. The
procedures were the same as the synthesis of Compound 122a. The
product 122c was obtained as a pale-yellow solid at a yield of
95%.
(1H-benzimidazol-5-ylamino){4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl-
}acetonitrile (Compound 122d)
##STR00162##
[0073] The (1H-benzimidazol-5-ylamino)
{4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl}-acetonitrile 122d
was prepared from the addition of 1H-benzimidazol-5-amine 121,
TMSCN and Compound 120d. The procedures were the same as the
synthesis of Compound 122a. The product 122d was obtained as a
pale-yellow solid at a yield of 96%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(1,3-thiazol-2-yl)phenyl]ethane-1,2-di-
amine (Compound 123a)
##STR00163##
[0075] The Compound 122a (5.0 g, 15.08 mmol) was dissolved in
acetic acid (200 mL) and then stirred at 10.degree. C. for 5
minutes. The Raney Nickel reagent was added to the stirring
solution and refilled hydrogen three times. The reaction mixture
was stirred under hydrogen at 10.degree. C. for 8 hours. The
catalyst was removed by filtration through celite. The filtrate was
concentrated under reduced pressure to obtain the crude product.
The crude product was purified by column chromatography on silica
gel using methanol/dichloromethane (1/19) as eluent. The product
123a was obtained as a yellow viscous liquid at a yield of 60%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(4-methyl-1,3-thiazol-2-yl)phenyl]etha-
ne-1,2-diamine (Compound 123b)
##STR00164##
[0077] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(4-methyl-1,3-thiazol-2-yl)-
phenyl]ethane-1,2-diamine 123b was prepared from the hydrogenation
of Compound 122b with the Raney Nickel reagent as catalyst. The
procedures were the same as the synthesis of Compound 123a. The
product 123b was obtained as a yellow viscous liquid at a yield of
50%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(4-cyclopropyl-1,3-thiazol-2-yl)phenyl-
]ethane-1,2-diamine (Compound 123c)
##STR00165##
[0079] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(4-cyclopropyl-1,3-thiazol--
2-yl)phenyl]ethane-1,2-diamine 123c was prepared from the
hydrogenation of Compound 122c with the Raney Nickel reagent as
catalyst. The procedures were the same as the synthesis of Compound
123a. The product 123c was obtained as a yellow viscous liquid at a
yield of 54%.
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]-
phenyl}ethane-1,2-diamine (Compound 123d)
##STR00166##
[0081] The
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[4-(trifluoromethyl)-1,3-th-
iazol-2-yl]phenyl}-ethane-1,2-diamine 123d was prepared from the
hydrogenation of Compound 122d with the Raney Nickel reagent as
catalyst. The procedures were the same as the synthesis of Compound
123a. The product 123d was obtained as a yellow viscous liquid at a
yield of 40%.
1-(1H-benzimidazol-5-yl)-5-[4-(1,3-thiazol-2-yl)phenyl]imidazolidin-2-one
(Compound 1)
##STR00167##
[0083] To the solution of 1,1'-carbonyl diimidazole (2.21 g, 20.5
mmol) and trimethylamine (7.5 mL) in anhydrous THF (100 mL), the
solution of Compound 123a (4.56 g, 13.6 mmol) in anhydrous THF (100
mL) was added dropwise by additional funnel at room temperature.
The resulting mixture was heated to 75.degree. C. and stirred for
18 hours. After cooling to room temperature, the reaction mixture
was concentrated under reduced pressure. The crude residue was
purified by column chromatography on silica gel using
methanol/dichloromethane (1/19) as eluent. The product (Compound 1)
was obtained as a white solid at a yield of 70%. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 3.39 (dd, 1H, J=7.0, 9.2 Hz), 4.02 (dd,
1H, J=9.2, 9.2 Hz), 5.55 (dd, 1H, J=7.0, 9.2 Hz), 7.31 (d, 1H,
J=8.8 Hz), 7.48 (d, 1H, J=8.8 Hz), 7.52 (d, 2H, J=8.2 Hz), 7.56 (s,
1H), 7.57 (s, 1H), 7.82 (d, 1H, J=3.6 Hz), 7.88 (d, 2H, J=8.2 Hz),
8.06 (s, 1H); LC/MS (ESI) m/z: 362.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-[4-(4-methyl-1,3-thiazol-2-yl)phenyl]imidazolid-
in-2-one (Compound 2)
##STR00168##
[0085] The
1-(1H-benzimidazol-5-yl)-5-[4-(4-methyl-1,3-thiazol-2-yl)phenyl-
]imidazolidin-2-one (Compound 2) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 123b. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 2) was obtained as a white solid at a yield of
66%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.37 (s, 3H), 3.13
(dd, 1H, J=6.6, 8.8 Hz), 3.87 (dd, 1H, J=8.8, 9.2 Hz), 5.58 (dd,
1H, J=6.6, 9.2 Hz), 7.01 (s, 1H), 7.27 (s, 2H), 7.40 (s, 1H), 7.46
(d, 2H, J=8.2 Hz), 7.57 (s, 1H), 7.83 (d, 2H, J=8.2 Hz), 8.07 (s,
1H); LC/MS (ESI) m/z: 376.2 [M+H]+.
1-(1H-benzimidazol-5-yl)-5-[4-(4-cyclopropyl-1,3-thiazol-2-yl)phenyl]imida-
zolidin-2-one (Compound 3)
##STR00169##
[0087] The
1-(1H-benzimidazol-5-yl)-5-[4-(4-cyclopropyl-1,3-thiazol-2-yl)p-
henyl]imidazolidin-2-one (Compound 3) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 123c. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 3) was obtained as a white solid at a yield of
71%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 0.80-0.84 (m, 2H),
0.85-0.90 (m, 2H), 2.05-2.09 (m, 1H), 3.12 (dd, 1H, J=6.4, 8.8 Hz),
3.87 (dd, 1H, J=8.8, 9.2 Hz), 5.57 (dd, 1H, J=6.4, 9.2 Hz), 7.02
(s, 1H), 7.26 (s, 2H), 7.39 (d, 1H, J=8.4 Hz), 7.45 (d, 2H, J=7.8
Hz), 7.55 (s, 1H), 7.79 (d, 2H, J=7.8 Hz), 8.07 (s, 1H), 12.27 (s,
1H); LC/MS (ESI) m/z: 402.2 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl-
}imidazolidin-2-one (Compound 4)
##STR00170##
[0089] The
1-(1H-benzimidazol-5-yl)-5-{4-[4-(trifluoromethyl)-1,3-thiazol--
2-yl]phenyl}-imidazolidin-2-one (Compound 4) was prepared from the
cycloaddition of carbonyl diimidazole and Compound 123d. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 4) was obtained as a white solid at a yield of
67%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.14 (dd, 1H,
J=6.3, 8.7 Hz), 3.89 (dd, 1H, J=8.7, 9.0 Hz), 5.62 (dd, 1H, J=6.3,
9.0 Hz), 7.02 (d, 1H, J=8.7 Hz), 7.28 (s, 1H), 7.40 (d, 1H, J=8.7
Hz), 7.52 (d, 2H, J=8.1 Hz), 7.57 (s, 1H), 7.92 (d, 2H, J=8.1 Hz),
8.08 (s, 1H), 8.50 (s, 1H), 12.21 (s, 1H); LC/MS (ESI) m/z: 430.2
[M+H]+.
4-bromo-2-cyclopropyl-1,3-thiazole (Compound 126)
##STR00171##
[0091] The palladium acetate (0.025 g, 0.11 mmol) and Xantphos
(0.066 g, 0.11 mmol) were added in THF (22 mL) that degassed under
argon. Then, the reaction mixture was stirred at room temperature
for 5 minutes. The 2,4-dibromo-1,3-thiazole 124 (1.09 g, 4.50
mmol), cyclopropylboronic acid 125 (0.58 g, 6.70 mmol) and
potassium phosphate (2.86 g) were added to the reaction mixture and
flushed with argon. The reaction mixture was stirred at 70.degree.
C. for 15 hours. After cooling to room temperature, the reaction
mixture was filtered and washed with dichloromethane. The filtrate
was concentrated under reduced pressure and purified by column
chromatography on silica gel using hexane as eluent. The product
126 was obtained as a colorless oil at a yield of 81%.
4-(2-cyclopropyl-1,3-thiazol-4-yl)benzaldehyde (Compound 127)
##STR00172##
[0093] The (4-formylphenyl)boronic acid 118 (0.33 g, 2.2 mmol),
4-bromo-2-cyclopropyl-1,3-thiazole 126 (0.41 g, 2.0 mmol),
Pd(dppf)Cl.sub.2 (0.08 g, 0.1 mmol), potassium carbonate (0.41 g)
and 1,2-dimethoxyethane (20 mL) were added to a 50 mL round-bottom
flask under nitrogen. The reaction mixture was stirred at
80.degree. C. for 16 hours and then cooled to room temperature. The
reaction mixture was partitioned between ethyl acetate and water.
The organic layers were collected, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The residue was
purified by column chromatography on silica gel using hexane/ether
(10/1) as eluent. The product 127 was obtained as a white solid at
a yield of 55%. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 1.10-1.16
(m, 4H), 2.32-2.39 (m, 1H), 7.40 (s, 1H), 7.89 (d, 2H, J=8.4 Hz),
8.03 (d, 2H, J=8.4 Hz), 10.01 (s, 1H); LC/MS (ESI) m/z: 230.1
[M+H].sup.+.
(1H-benzimidazol-5-ylamino)
[4-(2-cyclopropyl-1,3-thiazol-4-yl)phenyl]acetonitrile (Compound
128)
##STR00173##
[0095] The
(1H-benzimidazol-5-ylamino)[4-(2-cyclopropyl-1,3-thiazol-4-yl)p-
henyl]acetonitrile 128 was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 127. The procedures
were the same as the synthesis of Compound 122a. The product 128
was obtained as a pale-yellow solid at a yield of 93%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(2-cyclopropyl-1,3-thiazol-4-yl)phenyl-
]ethane-1,2-diamine (Compound 129)
##STR00174##
[0097] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(2-cyclopropyl-1,3-thiazol--
4-yl)phenyl]ethane-1,2-diamine 129 was prepared from the
hydrogenation of Compound 128 with the Raney Nickel reagent as
catalyst. The procedures were the same as the synthesis of Compound
123a. The product 129 was obtained as a yellow viscous liquid at a
yield of 52%.
1-(1H-benzimidazol-5-yl)-5-[4-(2-cyclopropyl-1,3-thiazol-4-yl)phenyl]imida-
zolidin-2-one (Compound 5)
##STR00175##
[0099] The
1-(1H-benzimidazol-5-yl)-5-[4-(2-cyclopropyl-1,3-thiazol-4-yl)p-
henyl]imidazolidin-2-one (Compound 5) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and product (129). The
procedures were the same as the synthesis of Compound 1. The
product (Compound 5) was obtained as a white solid at a yield of
73%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.93-0.98 (m, 2H),
1.08-1.16 (m, 2H), 2.34-2.42 (m, 1H), 3.13 (dd, 1H, J=6.6, 9.0 Hz),
3.85 (dd, 1H, J=8.7, 9.0 Hz), 5.52 (dd, 1H, J=6.6, 8.7 Hz), 6.98
(s, 1H), 7.25 (d, 1H, J=8.1 Hz), 7.37-7.40 (m, 3H), 7.54 (s, 1H),
7.72 (s, 1H), 7.80 (d, 2H, J=8.1 Hz), 8.07 (s, 1H), 12.24 (s, 1H);
LC/MS (ESI) m/z: 402.2 [M+H]+.
4-Glycylbenzonitrile hydrochloride (Compound 131)
##STR00176##
[0101] The 4-(bromoacetyl)benzonitrile 130 (22.4 g, 100 mmol) and
hexamethylenetetramine (HMTA, 15.4 g, 110 mmol) were dissolved in
chloroform (900 mL). The reaction mixture was stirred at room
temperature overnight. The precipitates were filtered and washed
with ethanol and ether. The resulting solids were suspended in the
mixture of HCl/ethanol (48 mL/240 mL) and then stirred at
75.degree. C. overnight. The precipitates were filtered when the
solution was still warm. The filtrate was concentrated to remove
solvents. Some acetone (100 mL) was added and stirred for an hour.
The precipitates were filtered and washed with acetone and ether.
The product 131 was obtained as an off-white solid in a quantum
yield and without further purification. 1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 4.62 (s, 2H), 8.06 (d, 2H, J=8.4 Hz), 8.16
(d, 2H, J=8.4 Hz), 8.59 (s, 2H); LC/MS (ESI) m/z: 161.1 [M+H]+.
N-[2-(4-cyanophenyl)-2-oxoethyl]acetamide (Compound 133a)
##STR00177##
[0103] The triethylamine (21 mL) was added to the suspending
solution of Compound 131 (10 g, 50.85 mmol) in dichloromethane (330
mL) and stirred at room temperature for 10 minutes. The acetic
anhydride (7.79 g, 76.28 mmol) was diluted in dichloromethane (20
mL) and then added to the reaction solution during 30 minutes by
additional funnel at an ice-bath. The resulting mixture was
continuously stirred at room temperature for an hour. The reaction
was quenched by water and extracted with dichloromethane. The
organic layers were collected, dried over sodium sulfate, filtered
and concentrated under reduced pressure. The crude residue was
purified by column chromatography on silica gel using ethyl
acetate/hexane (1/2) as eluent. The product 133a was obtained as a
yellow solid at a yield of 70%.
N-[2-(4-cyanophenyl)-2-oxoethyl]cyclopropanecarboxamide (Compound
133b)
##STR00178##
[0105] The N-[2-(4-cyanophenyl)-2-oxoethyl]cyclopropanecarboxamide
133b was prepared from the acetylation of Compound 131 with
cyclopropanecarboxylic anhydride 132b. The procedures were the same
as the synthesis of Compound 133a. The product 133b was obtained as
a yellow solid at a yield of 73%. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 0.65-0.68 (m, 4H), 1.70 (m, 1H), 4.64 (d, 2H,
J=5.4 Hz), 8.01 (d, 2H, J=8.4 Hz), 8.10 (d, 2H, J=8.4 Hz), 8.51 (t,
1H, d, J=5.4 Hz); LC/MS (ESI) m/z: 229.1 [M+H]+.
N-[2-(4-cyanophenyl)-2-oxoethyl]-2,2,2-trifluoroacetamide (Compound
133c)
##STR00179##
[0107] The
N-[2-(4-cyanophenyl)-2-oxoethyl]-2,2,2-trifluoroacetamide 133c was
prepared from the acetylation of Compound 131 with trifluoroacetic
anhydride 132c. The procedures were the same as the synthesis of
Compound 133a. The product 133c was obtained as a yellow solid at a
yield of 73%.
4-(2-methyl-1,3-thiazol-5-yl)benzonitrile (Compound 134a)
##STR00180##
[0109] The Compound 133a (0.3 g, 1.48 mmol) and Lawesson's reagent
(0.9 g, 2.22 mmol) were dissolved in THF (20 mL). The reaction
mixture was refluxed and stirred for 17 hours. After removing the
solvent, the crude residue was purified by column chromatography on
silica gel using ethyl acetate/hexane (1/10) as eluent. The product
134a was obtained as a yellow solid at a yield of 70%.
4-(2-cyclopropyl-1,3-thiazol-5-yl)benzonitrile (Compound 134b)
##STR00181##
[0111] The 4-(2-cyclopropyl-1,3-thiazol-5-yl)benzonitrile 134b was
prepared from the cyclization of Compound 133b with the Lawesson's
reagent in THF. The procedures were the same as the synthesis of
Compound 134a. The product 134b was obtained as a yellow solid at a
yield of 67%. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 1.10-1.21
(m, 4H), 2.31-2.35 (m, 1H), 7.59 (d, 2H, J=8.4 Hz), 7.66 (d, 2H,
J=8.4 Hz), 7.84 (s, 1H); LC/MS (ESI) m/z: 227.1 [M+H]+.
4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]benzonitrile (Compound
134c)
##STR00182##
[0113] The 4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]benzonitrile
134c was prepared from the cyclization of Compound 133c with the
Lawesson's reagent in toluene. The procedures were the same as the
synthesis of Compound 134a. The product 134c was obtained as a
yellow solid at a yield of 65%. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.68 (d, 2H, J=8.8 Hz), 7.74 (d, 2H, J=8.8 Hz), 8.15 (s,
1H); LC/MS (ESI) m/z: 255.1 [M+H]+.
4-(2-methyl-1,3-thiazol-5-yl)benzaldehyde (Compound 135a)
##STR00183##
[0115] To a solution of Compound 134a (1.57 g, 7.86 mmol) in
anhydrous toluene (100 mL) that cooled at -70.degree. C., the
solution of DIBAL-H in toluene (1.2M, 13.1 mL) was added dropwise
by using additional funnel. The reaction mixture was stirred at
-70.degree. C. under argon for an hour and then quenched with 1N
HCl.sub.(aq) (20 mL). The reaction mixture was stirred continuously
at room temperature overnight. The reaction mixture was partition
between ethyl acetate and water. The organic layers were collected,
washed with brine, dried over sodium sulfate, filtered and
concentrated under reduced pressure. The crude residue was purified
by column chromatography on silica gel using ethyl acetate/hexane
(1/5) as eluent. The product 135a was obtained as a yellow solid at
a yield of 63%.
4-(2-cyclopropyl-1,3-thiazol-5-yl)benzaldehyde (Compound 135b)
##STR00184##
[0117] The 4-(2-cyclopropyl-1,3-thiazol-5-yl)benzaldehyde 135b was
prepared from the reduction of Compound 134b with the DIBAL-H
reagent. The procedures were the same as the synthesis of Compound
135a. The product 135b was obtained as a yellow solid at a yield of
66%. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 1.13-1.20 (m, 4H),
2.31-2.35 (m, 1H), 7.65 (d, 2H, J=6.9 Hz), 7.87-7.89 (m, 3H), 9.99
(s, 1H); LC/MS (ESI) m/z: 230.1 [M+H].sup.+.
4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]benzaldehyde (Compound
135c)
##STR00185##
[0119] The 4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]benzaldehyde
135c was prepared from the reduction of Compound 134c with the
DIBAL-H reagent. The procedures were the same as the synthesis of
Compound 135a. The product 135c was obtained as a yellow solid at a
yield of 65%.
(1H-benzimidazol-5-ylamino)
[4-(2-methyl-1,3-thiazol-5-yl)phenyl]acetonitrile (Compound
136a)
##STR00186##
[0121] The
(1H-benzimidazol-5-ylamino)[4-(2-methyl-1,3-thiazol-5-yl)phenyl-
]acetonitrile 136a was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 135a. The
procedures were the same as the synthesis of Compound 122a. The
product 136a was obtained as a pale-yellow solid at a yield of
90%.
(1H-benzimidazol-5-ylamino)
[4-(2-cyclopropyl-1,3-thiazol-5-yl)phenyl]acetonitrile (Compound
136b)
##STR00187##
[0123] The
(1H-benzimidazol-5-ylamino)[4-(2-cyclopropyl-1,3-thiazol-5-yl)p-
henyl]acetonitrile 136b was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 135b. The
procedures were the same as the synthesis of Compound 122a. The
product 136b was obtained as a pale-yellow solid at a yield of
92%.
(1H-benzimidazol-5-ylamino){4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl-
}acetonitrile (Compound 136c)
##STR00188##
[0125] The (1H-benzimidazol-5-ylamino)
{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl}-acetonitrile 136c
was prepared from the addition of 1H-benzimidazol-5-amine 121,
TMSCN and Compound 135c. The procedures were the same as the
synthesis of Compound 122a. The product 136c was obtained as a
pale-yellow solid at a yield of 90%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(2-methyl-1,3-thiazol-5-yl)phenyl]etha-
ne-1,2-diamine (Compound 137a)
##STR00189##
[0127] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(2-methyl-1,3-thiazol-5-yl)-
phenyl]ethane-1,2-diamine 137a was prepared from the hydrogenation
of Compound 136a with the Raney Nickel reagent as catalyst. The
procedures were the same as the synthesis of Compound 123a. The
product 137a was obtained as a yellow viscous liquid at a yield of
50%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(2-cyclopropyl-1,3-thiazol-5-yl)phenyl-
]ethane-1,2-diamine (Compound 137b)
##STR00190##
[0129] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(2-cyclopropyl-1,3-thiazol--
5-yl)phenyl]ethane-1,2-diamine 137b was prepared from the
hydrogenation of Compound 136b with the Raney Nickel reagent as
catalyst. The procedures were the same as the synthesis of Compound
123a. The product 137b was obtained as a yellow viscous liquid at a
yield of 54%.
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]-
phenyl}ethane-1,2-diamine (Compound 137c)
##STR00191##
[0131] The
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[2-(trifluoromethyl)-1,3-th-
iazol-5-yl]phenyl}-ethane-1,2-diamine 137c was prepared from the
hydrogenation of Compound 136c with the Raney Nickel reagent as
catalyst. The procedures were the same as the synthesis of Compound
123a. The product 137c was obtained as a yellow viscous liquid at a
yield of 50%.
1-(1H-benzimidazol-5-yl)-5-[4-(2-methyl-1,3-thiazol-5-yl)phenyl]imidazolid-
in-2-one (Compound 6)
##STR00192##
[0133] The
1-(1H-benzimidazol-5-yl)-5-[4-(2-methyl-1,3-thiazol-5-yl)phenyl-
]imidazolidin-2-one (Compound 6) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 137a. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 6) was obtained as a white solid at a yield of
71%. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 2.64 (s, 3H),
3.30-3.36 (m, 1H), 3.97 (dd, 1H, J=8.6, 9.2 Hz), 5.48 (dd, 1H,
J=7.6, 8.6 Hz), 7.29 (d, 1H, J=8.8 Hz), 7.39 (d, 2H, J=8.0 Hz),
7.45-7.46 (m, 3H), 7.55 (s, 1H), 7.76 (s, 1H), 8.06 (s, 1H); LC/MS
(ESI) m/z: 376.3 [M+H]+.
1-(1H-benzimidazol-5-yl)-5-[4-(2-cyclopropyl-1,3-thiazol-5-yl)phenyl]imida-
zolidin-2-one (Compound 7)
##STR00193##
[0135] The
1-(1H-benzimidazol-5-yl)-5-[4-(2-cyclopropyl-1,3-thiazol-5-yl)p-
henyl]imidazolidin-2-one (Compound 7) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 137b. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 7) was obtained as a white solid at a yield of
74%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 0.92-0.95 (m, 2H),
1.06-1.11 (m, 2H), 2.32-2.39 (m, 1H), 3.10 (dd, 1H, J=6.4, 9.2 Hz),
3.84 (dd, 1H, J=8.4, 9.2 Hz), 5.53 (dd, 1H, J=6.4, 8.4 Hz), 6.99
(s, 1H), 7.26 (s, 1H), 7.37-7.39 (m, 3H), 7.50 (d, 2H, J=8.0 Hz),
7.54 (s, 1H), 7.88 (s, 1H), 8.07 (s, 1H), 12.23 (s, 1H); LC/MS
(ESI) m/z: 402.2 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl-
}imidazolidin-2-one (Compound 8)
##STR00194##
[0137] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(trifluoromethyl)-1,3-thiazol--
5-yl]phenyl}-imidazolidin-2-one (Compound 8) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 137c. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 8) was obtained as a white solid at a yield of
70%. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 3.37 (dd, 1H, J=7.2,
8.8 Hz), 4.01 (dd, 1H, J=8.8, 9.2 Hz), 5.56 (dd, 1H, J=7.2, 9.2
Hz), 7.31 (d, 1H, J=8.0 Hz), 7.47 (d, 1H, J=8.0 Hz), 7.50 (d, 2H,
J=8.4 Hz), 7.58 (s, 1H), 7.63 (d, 2H, J=8.4 Hz), 8.07 (s, 1H), 8.18
(s, 1H); LC/MS (ESI) m/z: 430.2 [M+H]+.
(5S)-1-(1H-benzimidazol-5-yl)-5-{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]p-
henyl}-imidazolidin-2-one (Compound 9)
##STR00195##
[0138]
(5R)-1-(1H-benzimidazol-5-yl)-5-{4-[2-(trifluoromethyl)-1,3-thiazol-
-5-yl]phenyl}-imidazolidin-2-one (Compound 10)
##STR00196##
[0140] The enantiomers (Compounds 9 and 10) were separated from
Compound 8 by HPLC using CHIRALPAK IC. The isomer fractions were
respectively collected and the optical pure isomers (Compounds 9
and 10) were thus obtained by removing the solvent under reduced
pressure. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 3.37 (dd, 1H,
J=7.2, 8.8 Hz), 4.01 (dd, 1H, J=8.8, 9.2 Hz), 5.56 (dd, 1H, J=7.2,
9.2 Hz), 7.31 (d, 1H, J=8.0 Hz), 7.47 (d, 1H, J=8.0 Hz), 7.50 (d,
2H, J=8.4 Hz), 7.58 (s, 1H), 7.63 (d, 2H, J=8.4 Hz), 8.07 (s, 1H),
8.18 (s, 1H); LC/MS (ESI) m/z: 430.2 [M+H]+.
4-(5-methylthiophen-2-yl)benzaldehyde (Compound 140a)
##STR00197##
[0142] The 4-bromobenzaldehyde 138a (1.85 g, 10.0 mmol),
2-methylthiophene 139a (1.96 g, 20.0 mmol), potassium acetate (1.96
g, 20.0 mmol) and palladium acetate (0.002 g, 0.01 mmol) were
dissolved in dimethylacetamide (DMA). The reaction mixture was
purged with argon and stirred at 150.degree. C. for 4 hours. The
reaction mixture was cooled to room temperature and extracted with
dichloromethane. The organic layers were collected, washed with
brine, dried over sodium sulfate, filtered and concentrated under
reduced pressure. The crude residue was purified by column
chromatography on silica gel using pentane/ether (1/4) as eluent.
The product 140a was obtained as a white solid at a yield of
92%.
(1H-benzimidazol-5-ylamino)
[4-(5-methylthiophen-2-yl)phenyl]acetonitrile (Compound 141a)
##STR00198##
[0144] The
(1H-benzimidazol-5-ylamino)[4-(5-methylthiophen-2-yl)phenyl]ace-
tonitrile 141a was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 140a. The
procedures were the same as the synthesis of Compound 122a. The
product 141a was obtained as a pale-yellow solid at a yield of
90%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-methylthiophen-2-yl)phenyl]ethane-1-
,2-diamine (Compound 142a)
##STR00199##
[0146] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-methylthiophen-2-yl)phen-
yl]ethane-1,2-diamine 142a was prepared from the hydrogenation of
Compound 141a with the Raney Nickel reagent as catalyst. The
procedures were the same as the synthesis of Compound 123a. The
product 142a was obtained as a yellow viscous liquid at a yield of
55%.
1-(1H-benzimidazol-5-yl)-5-[4-(5-methylthiophen-2-yl)phenyl]imidazolidin-2-
-one (Compound 11)
##STR00200##
[0148] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-methylthiophen-2-yl)phenyl]imi-
dazolidin-2-one (Compound 11) was prepared from the cycloaddition
of 1,1'-carbonyl diimidazole and Compound 142a. The procedures were
the same as the synthesis of Compound 1. The product (Compound 11)
was obtained as a white solid at a yield of 63%. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 2.44 (s, 3H), 3.39 (dd, 1H, J=7.6, 8.8
Hz), 3.97 (dd, 1H, J=8.8, 9.2 Hz), 5.40 (dd, 1H, J=7.6, 9.2 Hz),
6.67 (d, 1H, J=3.0 Hz), 7.05 (d, 1H, J=3.0 Hz), 7.26 (d, 1H, J=8.8
Hz), 7.33 (d, 2H, J=8.0 Hz), 7.45-7.47 (m, 3H), 7.52 (s, 1H), 7.99
(s, 1H); LC/MS (ESI) m/z: 375.3 [M+H].sup.+.
4-acryloylbenzonitrile (Compound 144)
##STR00201##
[0150] The 4-acetylbenzonitrile 143 (0.73 g, 5.0 mmol),
FeCl.sub.3.6H.sub.2O (0.14 g, 0.5 mmol), K.sub.2S.sub.2O.sub.8 (2.7
g, 10.0 mmol) and DMA (20 mL) were sequentially added to the
round-bottle flask. The reaction mixture was stirred at 110.degree.
C. for 4 hours. Upon completion of the reaction (monitored by TLC),
the resulting mixture was diluted with ether and washed with brine.
The organic layers were dried over sodium sulfate, filtered and
concentrated under reduced pressure. The crude residue was purified
by column chromatography on silica gel using ethyl acetate/ether
(1/4) as eluent. The product 144 was obtained as an off-white solid
at a yield of 40%.
4-(4-oxopentanoyl)benzonitrile (Compound 146)
##STR00202##
[0152] The product 144 (2.0 g, 12.7 mmol), cyclopropanecarbaldehyde
(1.2 mL, 15.3 mmol), triethylamine (1.2 mL, 8.6 mmol) and
2-(2-hydroxyethyl)-3-methyl-4-benzylthiazolium chloride 145 (0.65
g, 15.2 mmol) were sequentially added to the round-bottle flask.
The reaction mixture was stirred at 70.degree. C. overnight. Upon
completion of the reaction (monitored by TLC), the resulting
mixture was partitioned between ether and water. The organic layers
were washed with water, 2 M HCl and brine. After drying over sodium
sulfate, filtering and concentrating in vacuo, the crude residue
was purified by column chromatography on silica gel using ethyl
acetate/hexane (1/3) as eluent. The product 146 was obtained as a
yellow liquid at a yield of 50%.
4-(5-cyclopropylthiophen-2-yl)benzonitrile (Compound 147)
##STR00203##
[0154] The 4-(5-cyclopropylthiophen-2-yl)benzonitrile 147 was
prepared from the cyclization of product 146 with the Lawesson's
reagent in THF. The procedures were the same as the synthesis of
Compound 134a. The product 147 was obtained as a yellow solid at a
yield of 75%.
4-(5-cyclopropylthiophen-2-yl)benzaldehyde (Compound 148)
##STR00204##
[0156] The 4-(5-cyclopropylthiophen-2-yl)benzaldehyde 148 was
prepared from the reduction of Compound 147 with the DIBAL-H
reagent. The procedures were the same as the synthesis of Compound
135a. The product 148 was obtained as a yellow solid at a yield of
64%.
(1H-benzimidazol-5-ylamino)
[4-(5-cyclopropylthiophen-2-yl)phenyl]acetonitrile (Compound
149)
##STR00205##
[0158] The
(1H-benzimidazol-5-ylamino)[4-(5-cyclopropylthiophen-2-yl)pheny-
l]acetonitrile 149 was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 148. The procedures
were the same as the synthesis of Compound 122a. The product 149
was obtained as a pale-yellow solid at a yield of 91%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-cyclopropylthiophen-2-yl)phenyl]eth-
ane-1,2-diamine (Compound 150)
##STR00206##
[0160] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-cyclopropylthiophen-2-yl-
)phenyl]ethane-1,2-diamine 150 was prepared from the hydrogenation
of Compound 149 with the Raney Nickel reagent as catalyst. The
procedures were the same as the synthesis of Compound 123a. The
product 150 was obtained as a yellow viscous liquid at a yield of
53%.
1-(1H-benzimidazol-5-yl)-5-[4-(5-cyclopropylthiophen-2-yl)phenyl]imidazoli-
din-2-one (Compound 12)
##STR00207##
[0162] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-cyclopropylthiophen-2-yl)pheny-
l]imidazolidin-2-one (Compound 12) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and product 150. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 12) was obtained as a white solid at a yield of
69%. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 0.67-0.71 (m, 2H),
0.96-1.01 (m, 2H), 2.03-2.09 (m, 1H), 3.36 (dd, 1H, J=6.8, 8.8 Hz),
3.97 (dd, 1H, J=8.8, 9.2 Hz), 5.45 (dd, 1H, J=6.8, 9.2 Hz), 6.69
(d, 1H, J=3.6 Hz), 7.08 (d, 1H, J=3.6 Hz), 7.29 (d, 1H, J=8.8 Hz),
7.36 (d, 2H, J=8.4 Hz), 7.46-7.49 (m, 3H), 7.54 (s, 1H), 8.06 (s,
1H); LC/MS (ESI) m/z: 401.3 [M+H].sup.+.
4-(thiophen-2-yl)benzaldehyde (Compound 152a)
##STR00208##
[0164] The 4-bromobenzaldehyde 138a (1.85 g, 10.0 mmol), thiophene
(6.72 g, 80.0 mmol), potassium acetate (1.96 g, 20.0 mmol) and
palladium acetate (0.002 g, 0.01 mmol) were dissolved in DMA (50
mL). The reaction mixture was purged with argon and stirred at
130.degree. C. for 20 hours. The reaction mixture was cooled to
room temperature and removed the solvent in vacuo. The crude
residue was purified by column chromatography on silica gel using
pentane/ether (1/4) as eluent. The product 152a was obtained as a
light-yellow solid at a yield of 60%.
4-(5-iodothiophen-2-yl)benzaldehyde (Compound 153a)
##STR00209##
[0166] The Compound 152a (0.94 g, 5.0 mmol) and N-iodosuccinimide
(2.81 g, 12.5 mmol) were added to the 500 mL flask. The flask was
flushed with nitrogen and then added chloroform (200 mL) and acetic
acid (16 mL). The reaction mixture was stirred at room temperature
for 8 hours. The reaction mixture was washed with saturated sodium
thiosulfate solution (75 mL), saturated sodium bicarbonate solution
(75 mL), and water (75 mL). The organic layers were collected,
dried over sodium sulfate, filtered and concentrated in vacuo. The
crude residue was purified by column chromatography on silica gel
using dichloromethane/hexane (1/1) as eluent. The product 153a was
obtained as a yellow solid at a yield of 75%.
4-[5-(trifluoromethyl)thiophen-2-yl]benzaldehyde (Compound
155a)
##STR00210##
[0168] A mixture of Compound 153a (0.31 g, 1.0 mmol), methyl
difluoro(fluorosulfonyl)acetate 154 (0.96 g, 5.0 mmol), copper
iodide (0.23 g, 1.2 mmol), N-methylpyrrolidine (NMP, 1.2 mL) and
DMF (10 mL) was stirred at 70.degree. C. for 13 hours. The reaction
mixture was quenched with saturated aqueous ammonium chloride (15
mL), diluted with water (10 mL), filtered through celite, and
extracted with ethyl acetate. The organic layers were collected,
dried over sodium sulfate, filtered and concentrated in vacuo. The
crude residue was purified by column chromatography on silica gel
using ethyl acetate/hexane (1/6) as eluent. The product 155a was
obtained as a yellow solid at a yield of 70%.
(1H-benzimidazol-5-ylamino){4-[5-(trifluoromethyl)thiophen-2-yl]phenyl}ace-
tonitrile (Compound 156a)
##STR00211##
[0170] The (1H-benzimidazol-5-ylamino)
{4-[5-(trifluoromethyl)thiophen-2-yl]phenyl}-acetonitrile 156a was
prepared from the addition of 1H-benzimidazol-5-amine 121, TMSCN
and Compound 155a. The procedures were the same as the synthesis of
Compound 122a. The product 156a was obtained as a pale-yellow solid
at a yield of 88%.
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[5-(trifluoromethyl)thiophen-2-yl]phen-
yl}ethane-1,2-diamine (Compound 157a)
##STR00212##
[0172] The
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[5-(trifluoromethyl)thiophe-
n-2-yl]phenyl}ethane-1,2-diamine 157a was prepared from the
hydrogenation of Compound 156a with the Raney Nickel reagent as
catalyst. The procedures were the same as the synthesis of Compound
123a. The product 157a was obtained as a yellow viscous liquid at a
yield of 49%.
1-(1H-benzimidazol-5-yl)-5-{4-[5-(trifluoromethyl)thiophen-2-yl]phenyl}imi-
dazolidin-2-one (Compound 13)
##STR00213##
[0174] The
1-(1H-benzimidazol-5-yl)-5-{4-[5-(trifluoromethyl)thiophen-2-yl-
]phenyl}-imidazolidin-2-one (Compound 13) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 157a. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 13) was obtained as a white solid at a yield of
67%. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.36 (dd, 1H, J=6.9,
9.3 Hz), 3.99 (dd, 1H, J=9.3, 9.3 Hz), 5.51 (dd, 1H, J=6.9, 9.3
Hz), 7.29-7.32 (m, 2H), 7.43-7.48 (m, 4H), 7.55-7.60 (m, 3H), 8.06
(s, 1H); LC/MS (ESI) m/z: 429.2 [M+H].sup.+.
4-(thiophen-3-yl)benzaldehyde (Compound 159a)
##STR00214##
[0176] The 3-bromothiophene 158a (1.96 g, 12.0 mmol),
(4-formylphenyl)boronic acid 118 (2.70 g, 18.0 mmol), ethylene
glycol dimethyl ether (17 mL), water (10 mL) and sodium bicarbonate
(3.02 g, 36.0 mmol) were placed in a 50 mL round-bottom flask.
After adding Pd(PPh.sub.3).sub.4(0.69 g, 0.6 mmol) at room
temperature, the reaction mixture was refluxed for 5 hours. The
resulting mixture was extracted with ethyl acetate and water. The
organic layers were collected, washed with brine, dried over sodium
sulfate, filtered and concentrated under reduced pressure. The
crude residue was purified by column chromatography on silica gel
using toluene/hexane (2/1) as eluent. The product 159a was obtained
as a pale yellow oil at a yield of 95%.
4-(5-methylthiophen-3-yl)benzaldehyde (Compound 159b)
##STR00215##
[0178] The 4-(5-methylthiophen-3-yl)benzaldehyde 159b was prepared
from the Suzuki-Miyaura coupling of (4-formylphenyl)boronic acid
118 and 3-bromo-5-methylthiophene 158b. The procedures were the
same as the synthesis of Compound 159a. The product 159b was
obtained as a pale-yellow oil at a yield of 92%.
4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde (Compound
159c)
##STR00216##
[0180] The 4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde 159c
was prepared from the Suzuki-Miyaura coupling of
(4-formylphenyl)boronic acid 118 and
3-bromo-(5-trifluoromethyl)-thiophene 158c. The procedures were the
same as the synthesis of Compound 159a. The product 159c was
obtained as a pale-yellow oil at a yield of 85%.
(1H-benzimidazol-5-ylamino)[4-(thiophen-3-yl)phenyl]acetonitrile
(Compound 160a)
##STR00217##
[0182] The
(1H-benzimidazol-5-ylamino)[4-(thiophen-3-yl)phenyl]acetonitril- e
160a was prepared from the addition of 1H-benzimidazol-5-amine 121,
TMSCN and Compound 159a. The procedures were the same as the
synthesis of Compound 122a. The product 160a was obtained as a
pale-yellow solid at a yield of 92%.
(1H-benzimidazol-5-ylamino)
[4-(5-methylthiophen-3-yl)phenyl]acetonitrile (Compound 160b)
##STR00218##
[0184] The
(1H-benzimidazol-5-ylamino)[4-(5-methylthiophen-3-yl)phenyl]ace-
tonitrile 160b was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 159b. The
procedures were the same as the synthesis of Compound 122a. The
product 160b was obtained as a pale-yellow solid at a yield of
90%.
(1H-benzimidazol-5-ylamino){4-[5-(trifluoromethyl)thiophen-3-yl]phenyl}ace-
tonitrile (Compound 160c)
##STR00219##
[0186] The (1H-benzimidazol-5-ylamino)
{4-[5-(trifluoromethyl)thiophen-3-yl]phenyl}-acetonitrile 160c was
prepared from the addition of 1H-benzimidazol-5-amine 121, TMSCN
and Compound 159c. The procedures were the same as the synthesis of
Compound 122a. The product 160c was obtained as a pale-yellow solid
at a yield of 85%.
N-(1H-benzimidazol-5-yl)-1-[4-(thiophen-3-yl)phenyl]ethane-1,2-diamine
(Compound 161a)
##STR00220##
[0188] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(thiophen-3-yl)phenyl]ethan-
e-1,2-diamine 161a was prepared from the hydrogenation of Compound
160a with the Raney Nickel reagent as catalyst. The procedures were
the same as the synthesis of Compound 123a. The product was
obtained as a yellow viscous liquid at a yield of 53%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-methylthiophen-3-yl)phenyl]ethane-1-
,2-diamine (Compound 161b)
##STR00221##
[0190] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-methylthiophen-3-yl)phen-
yl]ethane-1,2-diamine 161b was prepared from the hydrogenation of
Compound 160b with the Raney Nickel reagent as catalyst. The
procedures were the same as the synthesis of Compound 123a. The
product 161b was obtained as a yellow viscous liquid at a yield of
50%.
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[5-(trifluoromethyl)thiophen-3-yl]phen-
yl}ethane-1,2-diamine (Compound 161c)
##STR00222##
[0192] The
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[5-(trifluoromethyl)thiophe-
n-3-yl]phenyl}ethane-1,2-diamine 161c was prepared from the
hydrogenation of Compound 160c with the Raney Nickel reagent as
catalyst. The procedures were the same as the synthesis of Compound
123a. The product 161c was obtained as a yellow viscous liquid at a
yield of 51%.
1-(1H-benzimidazol-5-yl)-5-[4-(thiophen-3-yl)phenyl]imidazolidin-2-one
(Compound 14)
##STR00223##
[0194] The
1-(1H-benzimidazol-5-yl)-5-[4-(thiophen-3-yl)phenyl]imidazolidi-
n-2-one (Compound 14) was prepared from the cycloaddition of
1,1'-carbonyl diimidazole and Compound 161a. The procedures were
the same as the synthesis of Compound 1. The product (Compound 14)
was obtained as a white solid at a yield of 73%. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 3.38 (dd, 1H, J=6.9, 9.0 Hz), 3.99 (dd,
1H, J=9.0, 9.3 Hz), 5.48 (dd, 1H, J=6.9, 9.3 Hz), 7.05 (s, 1H),
7.30 (d, 1H, J=8.4 Hz), 7.37-7.48 (m, 4H), 7.54-7.60 (m, 3H), 7.68
(s, 1H), 8.06 (s, 1H); LC/MS (ESI) m/z: 361.3 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-[4-(5-methylthiophen-3-yl)phenyl]imidazolidin-2-
-one (Compound 15)
##STR00224##
[0196] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-methylthiophen-3-yl)phenyl]imi-
dazolidin-2-one (Compound 15) was prepared from the cycloaddition
of 1,1'-carbonyl diimidazole and Compound 161b. The procedures were
the same as the synthesis of Compound 1. The product (Compound 15)
was obtained as a white solid at a yield of 75%. .sup.1H NMR (300
MHz, CD.sub.3OD) .delta. 2.40 (s, 3H), 3.30 (dd, 1H, J=7.5, 9.0
Hz), 3.90 (dd, 1H, J=9.0, 9.0 Hz), 5.38 (dd, 1H, J=7.5, 9.0 Hz),
6.95 (s, 1H), 7.17 (s, 1H), 7.26-7.31 (m, 3H), 7.42-7.45 (m, 3H),
7.55 (s, 1H), 8.03 (s, 1H); LC/MS (ESI) m/z: 375.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[5-(trifluoromethyl)thiophen-3-yl]phenyl}imi-
dazolidin-2-one (Compound 16)
##STR00225##
[0198] The
1-(1H-benzimidazol-5-yl)-5-{4-[5-(trifluoromethyl)thiophen-3-yl-
]phenyl}-imidazolidin-2-one (Compound 16) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 161c. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 16) was obtained as a white solid at a yield of
67%. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.36 (dd, 1H, J=6.9,
9.0 Hz), 3.99 (dd, 1H, J=9.0, 9.3 Hz), 5.50 (dd, 1H, J=6.9, 9.3
Hz), 7.30 (d, 1H, J=8.1 Hz), 7.41-7.47 (m, 3H), 7.56-7.58 (m, 3H),
7.81 (s, 2H), 8.05 (s, 1H); LC/MS (ESI) m/z: 429.1 [M+H].sup.+.
4-(5-bromothiophen-3-yl)benzaldehyde (Compound 162)
##STR00226##
[0200] Bromine (5.0 g, 32.0 mmol) in 50 mL of glacial acetic acid
was added dropwise to a solution of Compound 159a (6.0 g, 32.0
mmol) in 65 mL of glacial acetic acid. The resulting yellow
solution was stirred at room temperature for 2 days. The reaction
mixture was diluted with 300 mL of water and extracted with ethyl
acetate (100 mL.times.2). The combined organic layers were washed
with saturated aqueous sodium bicarbonate, dried over sodium
sulfate, filtered and concentrated under reduced pressure. The
crude residue was purified by column chromatography on silica gel
using ethyl acetate/hexane (1/9) as eluent. The product 162 was
obtained as a yellow solid at a yield of 73%.
4-(5-cyclopropylthiophen-3-yl)benzaldehyde (Compound 163)
##STR00227##
[0202] The palladium acetate (0.025 g, 0.11 mmol) and Xantphos
(0.066 g, 0.11 mmol) were added in THF (22 mL) that degassed under
argon. Then, the reaction mixture was stirred at room temperature
for 5 minutes. The 4-(5-bromothiophen-3-yl)benzaldehyde 162 (0.73
g, 3.0 mmol), cyclopropylboronic acid 125 (0.58 g, 6.70 mmol) and
potassium phosphate (2.86 g) were added to the reaction mixture and
flushed with argon. The reaction mixture was stirred at 70.degree.
C. for 15 hours. After cooling to room temperature, the reaction
mixture was filtered and washed with dichloromethane. The filtrate
was concentrated under reduced pressure and purified by column
chromatography on silica gel using hexane as eluent. The product
163 was obtained as a yellow solid at a yield of 84%.
(1H-benzimidazol-5-ylamino)
[4-(5-cyclopropylthiophen-3-yl)phenyl]acetonitrile (Compound
164)
##STR00228##
[0204] The
(1H-benzimidazol-5-ylamino)[4-(5-cyclopropylthiophen-3-yl)pheny-
l]acetonitrile 164 was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 163. The procedures
were the same as the synthesis of Compound 122a. The product 164
was obtained as a pale-yellow solid at a yield of 81%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-cyclopropylthiophen-3-yl)phenyl]eth-
ane-1,2-diamine (Compound 165)
##STR00229##
[0206] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-cyclopropylthiophen-3-yl-
)phenyl]ethane-1,2-diamine 165 was prepared from the hydrogenation
of Compound 164 with the Raney Nickel reagent as catalyst. The
procedures were the same as the synthesis of Compound 123a. The
product 165 was obtained as a yellow viscous liquid at a yield of
49%.
1-(1H-benzimidazol-5-yl)-5-[4-(5-cyclopropylthiophen-3-yl)phenyl]imidazoli-
din-2-one (Compound 17)
##STR00230##
[0208] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-cyclopropylthiophen-3-yl)pheny-
l]imidazolidin-2-one (Compound 17) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 165. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 17) was obtained as a white solid at a yield of
65%. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 0.59-0.63 (m, 2H),
0.91-0.96 (m, 2H), 2.00-2.09 (m, 1H), 3.39 (dd, 1H, J=6.9, 9.0 Hz),
4.00 (dd, 1H, J=9.0, 9.3 Hz), 5.50 (dd, 1H, J=6.9, 9.3 Hz), 6.69
(d, 1H, J=5.4 Hz), 7.05 (d, 1H, J=5.4 Hz), 7.32 (dd, 1H, J=1.8, 8.7
Hz), 7.41-7.45 (m, 3H), 7.46 (d, 2H, J=8.1 Hz), 7.58 (d, 1H, J=1.8
Hz), 8.06 (s, 1H); LC/MS (ESI) m/z: 401.2 [M+H].sup.+.
4-(1,3-dioxolan-2-yl)benzonitrile (Compound 167)
##STR00231##
[0210] To a round-bottom flask equipped with a Dean-Stark trap was
successively added 4-formylbenzonitrile 166 (7.68 g, 58.6 mmol), a
catalytic amount of p-TsOH (PTSA) and toluene (150 mL). After
stirring 5 minutes at room temperature, the monoethyleneglycol
(MEG) (13 mL, 234.3 mmol) was added dropwise. The reaction mixture
was refluxed for 3 hours and cooled to room temperature. After
removing toluene under reduced pressure, sat. Na.sub.2CO.sub.3(aq)
was added to quench the reaction and partitioned between DCM and
water. The organic phases were collected, washed with brine, dried
over sodium sulfate, filtered and concentrated under reduced
pressure. The viscous residue was treated with hexane at ice-bath
to form the product 167 as a yellow solid in a quantum yield.
4-(1,3-dioxolan-2-yl)-N'-hydroxybenzenecarboximidamide (Compound
168)
##STR00232##
[0212] To the solution of the Compound 167 (7.6 g, 43.4 mmol) in
ethanol/water (2/1, 75 mL), hydroxylamine hydrochloride (10.6 g,
151.8 mmol) and sodium carbonate (9.2 g, 86.8 mmol) were added at
room temperature. The reaction mixture was stirred at 100.degree.
C. for 2 hours. After concentrating under reduced pressure, the
residue was poured into water (50 mL) and stirred for 30 minutes.
The precipitates were filtered and washed with cold water to give
the product 168 as a white solid at a yield of 83%.
N'-[(cyclopropylcarbonyl)oxy]-4-(1,3-dioxolan-2-yl)benzenecarboximidamide
(Compound 169)
##STR00233##
[0214] To the suspension of the Compound 168 (1.8 g, 8.65 mmol) in
DCM (100 mL), pyridine (1.4 mL, 17.30 mmol) and
cyclopropanecarbonyl chloride (0.02 mL, 11.20 mmol) were added
dropwise under nitrogen at room temperature. The reaction mixture
was stirred at room temperature for 4 hours and then partitioned
between DCM and water. The organic phases were collected, washed
with brine, dried over sodium sulfate, filtered and concentrated
under reduced pressure. The crude residue was purified by column
chromatography on silica gel using DCM/methanol (9/1) as eluent to
give the product 169 as a white solid at a yield of 60%.
5-cyclopropyl-3-[4-(1,3-dioxolan-2-yl)phenyl]-1,2,4-oxadiazole
(Compound 170)
##STR00234##
[0216] The starting material 169 (1.1 g, 3.98 mmol) was dissolved
in toluene (40 mL). The reaction mixture was refluxed for 15 hours
and then cooled to room temperature. After removing the solvent
under reduced pressure, the crude residue was purified by column
chromatography on silica gel using EA/hexane (1/4) as eluent to
give the product 170 as a white solid at a yield of 70%.
4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)benzaldehyde (Compound
171)
##STR00235##
[0218] To the solution of the Compound 170 (1.2 g, 4.64 mmol) in
THF/H.sub.2O (4/1, 30 mL), the con. HCl was added dropwise. The
reaction mixture was stirred at 65.degree. C. for 6 hours and then
cooled to room temperature. The reaction mixture was partitioned
between DCM and water. The organic phases were collected, washed
with brine, dried over sodium sulfate, filtered and concentrated
under reduced pressure. The crude residue was purified by column
chromatography on silica gel using EA/hexane (1/9) as eluent to
give the product 171 as a white solid at a yield of 97%.
(1H-benzimidazol-5-ylamino)
[4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)phenyl]acetonitrile
(Compound 172)
##STR00236##
[0220] The
(1H-benzimidazol-5-ylamino)[4-(5-cyclopropyl-1,2,4-oxadiazol-3--
yl)phenyl]-acetonitrile 172 was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 171. The procedures
were the same as the synthesis of Compound 122a. The product 172
was obtained as a pale-yellow solid at a yield of 86%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)ph-
enyl]ethane-1,2-diamine (Compound 173)
##STR00237##
[0222] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-cyclopropyl-1,2,4-oxadia-
zol-3-yl)phenyl]ethane-1,2-diamine 173 was prepared from the
hydrogenation of Compound 172 with Pd/C as catalyst. The procedures
were the same as the synthesis of Compound 123a. The product 173
was obtained as a yellow viscous liquid at a yield of 55%.
1-(1H-benzimidazol-5-yl)-5-[4-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)phenyl]i-
midazolidin-2-one (Compound 18)
##STR00238##
[0224] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-cyclopropyl-1,2,4-oxadiazol-3--
yl)phenyl]-imidazolidin-2-one (Compound 18) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 173. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 18) was obtained as a white solid at a yield of
68%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.12-1.19 (m, 2H),
1.21-1.28 (m, 2H), 2.31-2.38 (m, 1H), 3.13 (dd, 1H, J=6.3, 8.7 Hz),
3.89 (dd, 1H, J=8.7, 9.0 Hz), 5.60 (dd, 1H, J=6.3, 9.0 Hz),
6.98-7.03 (m, 1H), 7.19 (br. s, 1H), 7.35-7.59 (m, 4H), 7.88 (d,
2H, J=7.8 Hz), 8.07 (s, 1H), 12.23 (s, 1H); LC/MS (ESI) m/z: 387.1
[M+H].sup.+.
4-(3-cyclopropyl-1,2-oxazol-5-yl)benzaldehyde (Compound 177)
##STR00239##
[0226] The cyclopropanecarboxaldehyde 174 (1.0 g, 14.26 mmol),
hydroxylamine hydrochloride (0.99 g, 14.26 mmol) and potassium
carbonate (2.17 g, 15.68 mmol) were dissolved in H.sub.2O (25 mL).
The reaction mixture was stirred at 85.degree. C. for 3 hours and
then cooled to room temperature. The reaction mixture was
partitioned between ether and water. The organic phases were
collected, washed with brine, dried over sodium sulfate, filtered
and concentrated under reduced pressure. The crude product 175 was
used in next step without any further purification. To the solution
of Compound 175 and NCS (1.9 g, 14.26 mmol) in DMF (30 mL), the
catalytic amount of pyridine was added under argon. The reaction
mixture was stirred at room temperature for 2 hours. After cooling
to 0.degree. C., 4-ethynylbenzaldehyde 176 (1.9 g, 14.26 mmol) and
triethylamine (3 mL) were added. The reaction mixture was
continuously stirred at room temperature for 3 hours. The reaction
mixture was partitioned between EA and water. The organic phases
were collected, washed with brine, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The crude residue
was purified by column chromatography on silica gel using EA/hexane
(1/8) as eluent to give the product 177 as a yellow solid at
overall yield of 54%.
(1H-benzimidazol-5-ylamino)
[4-(5-cyclopropyl-1,2-oxazol-3-yl)phenyl]acetonitrile (Compound
178)
##STR00240##
[0228] The
(1H-benzimidazol-5-ylamino)[4-(5-cyclopropyl-1,2-oxazol-3-yl)ph-
enyl]acetonitrile 178 was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 177. The procedures
were the same as the synthesis of Compound 122a. The product 178
was obtained as a pale-yellow solid at a yield of 83%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-cyclopropyl-1,2-oxazol-3-yl)phenyl]-
ethane-1,2-diamine (Compound 179)
##STR00241##
[0230] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-cyclopropyl-1,2-oxazol-3-
-yl)phenyl]ethane-1,2-diamine 179 was prepared from the
hydrogenation of Compound 178 with Pd/C as catalyst. The procedures
were the same as the synthesis of Compound 123a. The product 179
was obtained as a yellow viscous liquid at a yield of 49%.
1-(1H-benzimidazol-5-yl)-5-[4-(5-cyclopropyl-1,2-oxazol-3-yl)phenyl]imidaz-
olidin-2-one (Compound 19)
##STR00242##
[0232] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-cyclopropyl-1,2-oxazol-3-yl)ph-
enyl]imidazolidin-2-one (Compound 19) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 179. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 19) was obtained as a white solid at a yield of
58%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 0.75-0.79 (m, 2H),
0.99-1.04 (m, 2H), 1.98-2.02 (m, 1H), 3.13 (dd, 1H, J=6.3, 9.0 Hz),
3.88 (dd, 1H, J=8.7, 9.0 Hz), 5.59 (dd, 1H, J=6.3, 8.7 Hz), 6.68
(s, 1H), 7.01 (s, 1H), 7.26 (d, 1H, J=8.4 Hz), 7.40 (d, 1H, J=8.4
Hz), 7.49 (d, 2H, J=7.8 Hz), 7.56 (s, 1H), 7.72 (d, 2H, J=7.8 Hz),
7.79 (s, 1H), 8.08 (s, 1H); LC/MS (ESI) m/z: 386.2 [M+H].sup.+.
4-(2H-tetrazol-5-yl)benzaldehyde hydrochloride (Compound 180)
##STR00243##
[0234] To the solution of 4-formylbenzonitrile 166 (1.31 g, 10.0
mmol) in DMF (10 mL), sodium azide (0.72 g, 11 mmol) and ammonium
chloride (0.14 g, 2.5 mmol) were added under nitrogen. The reaction
mixture was refluxed overnight and then cooled to room temperature.
The reaction mixture was diluted with water and extracted with DCM.
The aqueous phase was chilled in ice and acidified by adding 1N
HCl.sub.(aq). After filtering, the precipitates were washed with
water and ether to obtain the product 180 as a yellow solid at a
yield of 94%.
4-(2-propyl-2H-tetrazol-5-yl)benzaldehyde (Compound 181a)
##STR00244##
[0236] To the suspension of the Compound 180 (2.1 g, 10.0 mmol) in
acetonitrile (20 mL), potassium carbonate (2.76 g, 20 mmol) and
1-bromopropane (2.46 g, 20 mmol) were added under nitrogen. The
reaction mixture was stirred at 50.degree. C. overnight and then
cooled to room temperature. The reaction mixture was partitioned
between EA and water. The organic phases were collected, washed
with brine, dried over sodium sulfate, filtered and concentrated
under reduced pressure. The crude residue was purified by column
chromatography on silica gel using EA/hexane (1/4) as eluent to
give the product 181a as a yellow solid at a yield of 76%.
4-[2-(propan-2-yl)-2H-tetrazol-5-yl]benzaldehyde (Compound
181b)
##STR00245##
[0237] Isopropanol (1.2 g, 20.0 mmol) was added to the solution of
the Compound 180 (2.1 g, 10.0 mmol) in trifluoromethanesulfonic
acid (20 mL) under nitrogen. The reaction mixture was stirred at
room temperature for an hour. The reaction mixture was poured into
water and treated with sat. NaHCO.sub.3(aq) until pH=8-9. The
mixture was partitioned between DCM and water. The organic phases
were collected, washed with brine, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The crude residue
was purified by column chromatography on silica gel using EA/hexane
(1/4) as eluent to give the product 181b as a yellow solid at a
yield of 54%.
(1H-benzimidazol-5-ylamino)
[4-(2-propyl-2H-tetrazol-5-yl)phenyl]acetonitrile (Compound
182a)
##STR00246##
[0239] The
(1H-benzimidazol-5-ylamino)[4-(2-propyl-2H-tetrazol-5-yl)phenyl-
]acetonitrile 182a was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and Compound 181a. The
procedures were the same as the synthesis of Compound 122a. The
product 182a was obtained as a pale-yellow solid at a yield of
86%.
(1H-benzimidazol-5-ylamino){4-[2-(propan-2-yl)-2H-tetrazol-5-yl]phenyl}ace-
tonitrile (Compound 182b)
##STR00247##
[0241] The (1H-benzimidazol-5-ylamino)
{4-[2-(propan-2-yl)-2H-tetrazol-5-yl]phenyl}-acetonitrile 182b was
prepared from the addition of 1H-benzimidazol-5-amine 121, TMSCN
and Compound 181b. The procedures were the same as the synthesis of
Compound 122a. The product 182b was obtained as a pale-yellow solid
at a yield of 81%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(2-propyl-2H-tetrazol-5-yl)phenyl]etha-
ne-1,2-diamine (Compound 183a)
##STR00248##
[0243] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(2-propyl-2H-tetrazol-5-yl)-
phenyl]ethane-1,2-diamine 183a was prepared from the hydrogenation
of Compound 182a with Pd/C as catalyst. The procedures were the
same as the synthesis of Compound 123a. The product 183a was
obtained as a yellow viscous liquid at a yield of 50%.
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[2-(propan-2-yl)-2H-tetrazol-5-yl]phen-
yl}ethane-1,2-diamine (Compound 183b)
##STR00249##
[0245] The
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[2-(propan-2-yl)-2H-tetrazo-
l-5-yl]phenyl}ethane-1,2-diamine 183b was prepared from the
hydrogenation of Compound 182b with Pd/C as catalyst. The
procedures were the same as the synthesis of Compound 123a. The
product 183b was obtained as a yellow viscous liquid at a yield of
45%.
1-(1H-benzimidazol-5-yl)-5-[4-(2-propyl-2H-tetrazol-5-yl)phenyl]imidazolid-
in-2-one (Compound 20)
##STR00250##
[0247] The
1-(1H-benzimidazol-5-yl)-5-[4-(2-propyl-2H-tetrazol-5-yl)phenyl-
]imidazolidin-2-one (Compound 20) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 183a. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 20) was obtained as a white solid at a yield of
60%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.83 (t, 3H, J=7.2
Hz), 1.87-1.99 (m, 2H), 3.14 (dd, 1H, J=6.3, 8.7 Hz), 3.89 (dd, 1H,
J=8.7, 9.0 Hz), 4.64 (t, 2H, J=7.2 Hz), 5.60 (dd, 1H, J=6.3, 9.0
Hz), 7.01 (s, 1H), 7.26 (d, 1H, J=8.9 Hz), 7.39 (d, 1H, J=8.9 Hz),
7.52-7.57 (m, 3H), 7.98 (d, 2H, J=8.4 Hz), 8.07 (s, 1H), 12.21 (s,
1H); LC/MS (ESI) m/z: 389.2 [M+H]+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(propan-2-yl)-2H-tetrazol-5-yl]phenyl}imi-
dazolidin-2-one (Compound 21)
##STR00251##
[0249] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(propan-2-yl)-2H-tetrazol-5-yl-
]phenyl}-imidazolidin-2-one (Compound 21) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and Compound 183b. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 21) was obtained as a white solid at a yield of
62%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.56 (d, 6H, J=6.4
Hz), 3.14 (dd, 1H, J=6.4, 8.8 Hz), 3.89 (dd, 1H, J=8.8, 9.2 Hz),
5.09-5.15 (m, 1H), 5.60 (dd, 1H, J=6.4, 9.2 Hz), 7.04 (s, 1H), 7.26
(d, 1H, J=7.6 Hz), 7.39 (d, 1H, J=8.8 Hz), 7.52-7.57 (m, 3H), 7.97
(d, 2H, J=8.4 Hz), 8.07 (s, 1H), 12.25 (s, 1H); LC/MS (ESI) m/z:
389.2 [M+H].sup.+.
3-fluoro-4-(thiophen-2-yl)benzaldehyde (Compound 152b)
##STR00252##
[0251] A mixture of tributyl(thiophen-2-yl)stannane 151 (6.62 g,
17.7 mmol), 4-bromo-3-fluorobenzaldehyde 138b (3.0 g, 14.8 mmol)
and Pd(PPh.sub.3).sub.4(0.51 g, 0.43 mmol) in toluene (160 mL) was
refluxed for 16 hours. After cooling to room temperature, the
solvent was removed under reduced pressure. The residue was diluted
with dichloromethane and filtered through celite. The organic phase
was washed with water, dried over sodium sulfate, filtered and
concentrated. The crude product was purified by column
chromatography on silica gel using dichloromethane/hexane (1/9) as
eluent. The product 152b was obtained as a pale-yellow solid at a
yield of 70%.
2-fluoro-4-(thiophen-2-yl)benzaldehyde (Compound 152c)
##STR00253##
[0253] The 2-fluoro-4-(thiophen-2-yl)benzaldehyde 152c was prepared
from the Suzuki-coupling of 4-bromo-2-fluorobenzaldehyde 138c and
tributyl(thiophen-2-yl)stannane 151 using Pd(PPh.sub.3).sub.4 as a
catalyst. The procedures were the same as the synthesis of the
Compound 152b. The product 152c was obtained as a pale-yellow solid
at a yield of 68%.
2,6-difluoro-4-(thiophen-2-yl)benzaldehyde (Compound 152d)
##STR00254##
[0255] The 2,6-difluoro-4-(thiophen-2-yl)benzaldehyde 152d was
prepared from the Suzuki-coupling of
4-bromo-2,6-difluorobenzaldehyde 138d and
tributyl(thiophen-2-yl)stannane 151 using Pd(PPh.sub.3).sub.4 as a
catalyst. The procedures were the same as the synthesis of the
Compound 152b. The product 152d was obtained as a pale-yellow solid
at a yield of 56%.
3-fluoro-4-(5-iodothiophen-2-yl)benzaldehyde (Compound 153b)
##STR00255##
[0257] The 3-fluoro-4-(5-iodothiophen-2-yl)benzaldehyde 153b was
prepared from the selective iodination of the Compound 152b using
N-iodosuccinimide. The procedures were the same as the synthesis of
the Compound 153a. The product 153b was obtained as a yellow-green
solid at a yield of 77%.
2-fluoro-4-(5-iodothiophen-2-yl)benzaldehyde (Compound 153c)
##STR00256##
[0259] The 2-fluoro-4-(5-iodothiophen-2-yl)benzaldehyde 153c was
prepared from the selective iodination of the Compound 152c using
N-iodosuccinimide. The procedures were the same as the synthesis of
the Compound 153a. The product 153c was obtained as a yellow-green
solid at a yield of 75%.
2,6-difluoro-4-(5-iodothiophen-2-yl)benzaldehyde (Compound
153d)
##STR00257##
[0261] The 2,6-difluoro-4-(5-iodothiophen-2-yl)benzaldehyde 153d
was prepared from the selective iodination of the Compound 152d
using N-iodosuccinimide. The procedures were the same as the
synthesis of the Compound 153a. The product 153d was obtained as a
yellow-green solid at a yield of 71%.
3-fluoro-4-[5-(trifluoromethyl)thiophen-2-yl]benzaldehyde (Compound
155b)
##STR00258##
[0263] The
3-fluoro-4-[5-(trifluoromethyl)thiophen-2-yl]benzaldehyde 155b was
prepared from the trifluoromethylation of the Compound 153b that
treated with methyl difluoro(fluorosulfonyl)acetate 154 and copper
iodide. The procedures were the same as the synthesis of the
Compound 155a. The product 155b was obtained as a yellow solid at a
yield of 70%.
2-fluoro-4-[5-(trifluoromethyl)thiophen-2-yl]benzaldehyde (Compound
155c)
##STR00259##
[0265] The
2-fluoro-4-[5-(trifluoromethyl)thiophen-2-yl]benzaldehyde 155c was
prepared from the trifluoromethylation of the Compound 153c that
treated with methyl difluoro(fluorosulfonyl)acetate 154 and copper
iodide. The procedures were the same as the synthesis of the
Compound 155a. The product 155c was obtained as a yellow solid at a
yield of 72%.
2,6-difluoro-4-[5-(trifluoromethyl)thiophen-2-yl]benzaldehyde
(Compound 155d)
##STR00260##
[0267] The
2,6-difluoro-4-[5-(trifluoromethyl)thiophen-2-yl]benzaldehyde 155d
was prepared from the trifluoromethylation of the Compound 153d
that treated with methyl difluoro(fluorosulfonyl)acetate 154 and
copper iodide. The procedures were the same as the synthesis of the
Compound 155a. The product 155d was obtained as a yellow solid at a
yield of 67%.
1-(1H-benzimidazol-5-yl)-5-{3-fluoro-4-[5-(trifluoromethyl)thiophen-2-yl]p-
henyl}-imidazolidin-2-one (Compound 22)
##STR00261##
[0269] The
1-(1H-benzimidazol-5-yl)-5-{3-fluoro-4-[5-(trifluoromethyl)thio-
phen-2-yl]phenyl}-imidazolidin-2-one (Compound 22) was prepared
from the Compound 155b in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 22) was obtained as a white solid
at an overall yield of 27%. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.36 (dd, 1H, J=6.9, 9.0 Hz), 4.01 (dd, 1H, J=9.0, 9.6 Hz),
5.54 (dd, 1H, J=6.9, 9.6 Hz), 7.27-7.34 (m, 3H), 7.41 (d, 1H, J=3.9
Hz), 7.48-7.51 (m, 2H), 7.59-7.67 (m, 2H), 8.07 (s, 1H); LC/MS
(ESI) m/z: 447.0 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{2-fluoro-4-[5-(trifluoromethyl)thiophen-2-yl]p-
henyl}-imidazolidin-2-one (Compound 23)
##STR00262##
[0271] The
1-(1H-benzimidazol-5-yl)-5-{2-fluoro-4-[5-(trifluoromethyl)thio-
phen-2-yl]phenyl}-imidazolidin-2-one (Compound 23) was prepared
from the Compound 155c in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 23) was obtained as a white solid
at an overall yield of 25%. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.44 (dd, 1H, J=6.0, 9.0 Hz), 4.05 (dd, 1H, J=9.0, 9.3 Hz),
5.83 (dd, 1H, J=6.0, 9.3 Hz), 7.31-7.51 (m, 7H), 7.60 (d, 1H, J=2.1
Hz), 8.08 (s, 1H); LC/MS (ESI) m/z: 447.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{2,6-difluoro-4-[5-(trifluoromethyl)thiophen-2--
yl]phenyl}-imidazolidin-2-one (Compound 24)
##STR00263##
[0273] The
1-(1H-benzimidazol-5-yl)-5-{2,6-difluoro-4-[5-(trifluoromethyl)-
thiophen-2-yl]phenyl}imidazolidin-2-one (Compound 24) was prepared
from the Compound 155d in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 24) was obtained as a white solid
at an overall yield of 21%. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.65 (dd, 1H, J=7.2, 9.3 Hz), 4.05 (dd, 1H, J=9.3, 10.5
Hz), 6.01 (dd, 1H, J=7.2, 10.5 Hz), 7.23-7.28 (m, 3H), 7.39-7.41
(m, 1H), 7.46-7.50 (m, 2H), 7.57 (d, 1H, J=1.8 Hz), 8.08 (s, 1H);
LC/MS (ESI) m/z: 465.1 [M+H].sup.+.
3-fluoro-4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde (Compound
159d)
##STR00264##
[0275] The
3-fluoro-4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde 159d was
prepared from the Suzuki-Miyaura coupling of
(2-fluoro-4-formylphenyl)boronic acid 118d and
3-bromo-(5-trifluoromethyl)thiophene 158c. The procedures were the
same as the synthesis of Compound 159a. The product 159d was
obtained as a pale-yellow solid at a yield of 60%.
2-fluoro-4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde (Compound
159e)
##STR00265##
[0277] The
2-fluoro-4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde 159e was
prepared from the Suzuki-Miyaura coupling of
(3-fluoro-4-formylphenyl)boronic acid 118e and
3-bromo-(5-trifluoromethyl)thiophene 158c. The procedures were the
same as the synthesis of Compound 159a. The product 159e was
obtained as a pale-yellow solid at a yield of 53%.
2,6-difluoro-4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde
(Compound 159f)
##STR00266##
[0279] The
2,6-difluoro-4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde 159f
was prepared from the Suzuki-Miyaura coupling of
(3,5-difluoro-4-formylphenyl)boronic acid 118f and
3-bromo-(5-trifluoromethyl)thiophene 158c. The procedures were the
same as the synthesis of Compound 159a. The product 159f was
obtained as a pale-yellow solid at a yield of 33%.
2,3-difluoro-4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde
(Compound 159g)
##STR00267##
[0281] The
2,3-difluoro-4-[5-(trifluoromethyl)thiophen-3-yl]benzaldehyde 159g
was prepared from the Suzuki-Miyaura coupling of
(2,3-difluoro-4-formylphenyl)boronic acid 118g and
3-bromo-(5-trifluoromethyl)thiophene 158c. The procedures were the
same as the synthesis of Compound 159a. The product 159g was
obtained as a pale-yellow solid at a yield of 29%.
1-(1H-benzimidazol-5-yl)-5-{3-fluoro-4-[5-(trifluoromethyl)thiophen-3-yl]p-
henyl}-imidazolidin-2-one (Compound 25)
##STR00268##
[0283] The
1-(1H-benzimidazol-5-yl)-5-{3-fluoro-4-[5-(trifluoromethyl)thio-
phen-3-yl]phenyl}-imidazolidin-2-one (Compound 25) was prepared
from the Compound 159d in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 25) was obtained as a white solid
at an overall yield of 25%. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.37 (dd, 1H, J=6.9, 9.0 Hz), 4.01 (dd, 1H, J=9.0, 9.3 Hz),
5.54 (dd, 1H, J=6.9, 9.3 Hz), 7.24-7.34 (m, 3H), 7.49 (d, 1H, J=8.7
Hz), 7.56-7.61 (m, 2H), 7.80 (d, 1H, J=0.9 Hz), 7.90 (s, 1H), 8.08
(s, 1H); LC/MS (ESI) m/z: 447.0 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{2-fluoro-4-[5-(trifluoromethyl)thiophen-3-yl]p-
henyl}-imidazolidin-2-one (Compound 26)
##STR00269##
[0285] The
1-(1H-benzimidazol-5-yl)-5-{2-fluoro-4-[5-(trifluoromethyl)thio-
phen-3-yl]phenyl}imidazolidin-2-one (Compound 26) was prepared from
the Compound 159e in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 26) was obtained as a white solid
at an overall yield of 27%. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.44 (dd, 1H, J=6.3, 9.0 Hz), 4.05 (dd, 1H, J=9.0, 9.6 Hz),
5.82 (dd, 1H, J=6.3, 9.6 Hz), 7.33 (dd, 1H, J=1.2, 8.7 Hz),
7.42-7.50 (m, 4H), 7.60 (d, 1H, J=2.0 Hz), 7.86 (d, 1H, J=1.2 Hz),
7.93 (d, 1H, J=2.0 Hz), 8.07 (s, 1H); LC/MS (ESI) m/z: 447.0
[M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{2,6-difluoro-4-[5-(trifluoromethyl)thiophen-3--
yl]phenyl}-imidazolidin-2-one (Compound 27)
##STR00270##
[0287] The
1-(1H-benzimidazol-5-yl)-5-{2,6-difluoro-4-[5-(trifluoromethyl)-
thiophen-3-yl]phenyl}imidazolidin-2-one (Compound 27) was prepared
from the Compound 159f in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 27) was obtained as a white solid
at an overall yield of 21%. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.65 (dd, 1H, J=7.2, 9.3 Hz), 4.04 (dd, 1H, J=9.3, 10.2
Hz), 6.00 (dd, 1H, J=7.2, 10.2 Hz), 7.24-7.28 (m, 3H), 7.48 (d, 1H,
J=8.7 Hz), 7.56 (d, 1H, J=1.8 Hz), 7.84 (s, 1H), 7.95 (d, 1H, J=1.8
Hz), 8.07 (s, 1H); LC/MS (ESI) m/z: 465.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{2,3-difluoro-4-[5-(trifluoromethyl)thiophen-3--
yl]phenyl}-imidazolidin-2-one (Compound 28)
##STR00271##
[0289] The
1-(1H-benzimidazol-5-yl)-5-{2,3-difluoro-4-[5-(trifluoromethyl)-
thiophen-3-yl]phenyl}imidazolidin-2-one (Compound 28) was prepared
from the Compound 159g in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 28) was obtained as a white solid
at an overall yield of 20%. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.46 (dd, 1H, J=6.3, 9.0 Hz), 4.07 (dd, 1H, J=9.0, 9.6 Hz),
5.87 (dd, 1H, J=6.3, 9.6 Hz), 7.23-7.40 (m, 3H), 7.50 (d, 1H, J=8.4
Hz), 7.61 (d, 1H, J=1.8 Hz), 7.82 (s, 1H), 7.97 (s, 1H), 8.09 (s,
1H); LC/MS (ESI) m/z: 465.1 [M+H]+.
4-(5-chlorothiophen-2-yl)benzaldehyde (Compound 140b)
##STR00272##
[0291] The 4-(5-chlorothiophen-2-yl)benzaldehyde 140b was prepared
from the Suzuki-coupling of 4-bromobenzaldehyde 138a and
2-chlorothiophene 139b. The procedures were the same as the
synthesis of Compound 140a. The product 140b was obtained as a
yellow solid at a yield of 74%.
4-(5-chlorothiophen-2-yl)-3-fluorobenzaldehyde (Compound 140c)
##STR00273##
[0293] The 4-(5-chlorothiophen-2-yl)-3-fluorobenzaldehyde 140c was
prepared from the Suzuki-coupling of 4-bromo-3-fluorobenzaldehyde
138b and 2-chlorothiophene 139b. The procedures were the same as
the synthesis of Compound 140a. The product 140c was obtained as a
yellow solid at a yield of 69%.
4-(5-chlorothiophen-2-yl)-2-fluorobenzaldehyde (Compound 140d)
##STR00274##
[0295] The 4-(5-chlorothiophen-2-yl)-2-fluorobenzaldehyde 140d was
prepared from the Suzuki-coupling of 4-bromo-2-fluorobenzaldehyde
138c and 2-chlorothiophene 139b. The procedures were the same as
the synthesis of Compound 140a. The product 140d was obtained as a
yellow solid at a yield of 67%.
4-(5-chlorothiophen-2-yl)-2,6-difluorobenzaldehyde (Compound
140e)
##STR00275##
[0297] The 4-(5-chlorothiophen-2-yl)-2,6-difluorobenzaldehyde 140e
was prepared from the Suzuki-coupling of
4-bromo-2,6-fluorobenzaldehyde 138d and 2-chlorothiophene 139b. The
procedures were the same as the synthesis of Compound 140a. The
product 140e was obtained as a yellow solid at a yield of 60%.
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-2-yl)phenyl]imidazolidin-2-
-one (Compound 29)
##STR00276##
[0299] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-2-yl)phenyl]imi-
dazolidin-2-one (Compound 29) was prepared from the Compound 140b
in three-steps synthesis of imidazolidinone formation. The
procedures were the same as the synthesis of Compound 1. The
product (Compound 29) was obtained as a white solid at an overall
yield of 28%. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.36 (dd,
1H, J=6.9, 9.0 Hz), 3.99 (dd, 1H, J=9.0, 9.3 Hz), 5.48 (dd, 1H,
J=6.9, 9.3 Hz), 6.90 (d, 1H, J=3.9 Hz), 7.12 (d, 1H, J=3.9 Hz),
7.30 (d, 1H, J=9.0 Hz), 7.40 (d, 2H, J=8.4 Hz), 7.45-7.49 (m, 3H),
7.54 (d, 1H, J=2.1 Hz), 8.06 (s, 1H); LC/MS (ESI) m/z: 395.0
[M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-2-yl)-3-fluorophenyl]imida-
zolidin-2-one (Compound 30)
##STR00277##
[0301] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-2-yl)-3-fluorop-
henyl]-imidazolidin-2-one (Compound 30) was prepared from the
Compound 140c in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 30) was obtained as a white solid
at an overall yield of 24%. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 3.36 (dd, 1H, J=6.8, 9.2 Hz), 4.00 (dd, 1H, J=9.2, 9.2 Hz),
5.52 (dd, 1H, J=6.8, 9.2 Hz), 6.95 (d, 1H, J=4.0 Hz), 7.23-7.26 (m,
3H), 7.31 (d, 1H, J=8.0 Hz), 7.49 (d, 1H, J=8.4 Hz), 7.56-7.59 (m,
2H), 8.08 (s, 1H); LC/MS (ESI) m/z: 413.0 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-2-yl)-2-fluorophenyl]imida-
zolidin-2-one (Compound 31)
##STR00278##
[0303] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-2-yl)-2-fluorop-
henyl]-imidazolidin-2-one (Compound 31) was prepared from the
Compound 140d in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 31) was obtained as a white solid
at an overall yield of 25%. .sup.1H NMR (300 MHz, CD.sub.3OD)
.delta. 3.42 (dd, 1H, J=6.6, 9.0 Hz), 4.03 (dd, 1H, J=9.0, 9.6 Hz),
5.78 (dd, 1H, J=6.6, 9.6 Hz), 6.91 (d, 1H, J=4.2 Hz), 7.17 (d, 1H,
J=4.2 Hz), 7.24-7.42 (m, 4H), 7.48 (d, 1H, J=8.4 Hz), 7.58 (d, 1H,
J=1.8 Hz), 8.07 (s, 1H); LC/MS (ESI) m/z: 413.0 [M+H]+.
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-2-yl)-2,6-difluorophenyl]i-
midazolidin-2-one (Compound 32)
##STR00279##
[0305] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-2-yl)-2,6-diflu-
orophenyl]-imidazolidin-2-one (Compound 32) was prepared from the
Compound 140e in three-steps synthesis of imidazolidinone
formation. The procedures were the same as the synthesis of
Compound 1. The product (Compound 32) was obtained as a white solid
at an overall yield of 20%.
(5R)-1-(1H-benzimidazol-5-yl)-5-{4-[5-(trifluoromethyl)thiophen-2-yl]pheny-
l}imidazolidin-2-one (Compound 33)
##STR00280##
[0306]
(5S)-1-(1H-benzimidazol-5-yl)-5-{4-[5-(trifluoromethyl)thiophen-2-y-
l]phenyl}imidazolidin-2-one (Compound 34)
##STR00281##
[0308] The enantiomers (Compounds 33 and 34) were separated from
Compound 13 by HPLC using CHIRALPAK AD-H. The isomer fractions were
respectively collected and the optical pure isomers (Compounds 33
and 34) were thus obtained by removing the solvent under reduced
pressure. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.36 (dd, 1H,
J=6.9, 9.3 Hz), 3.99 (dd, 1H, J=9.3, 9.3 Hz), 5.51 (dd, 1H, J=6.9,
9.3 Hz), 7.29-7.32 (m, 2H), 7.43-7.48 (m, 4H), 7.55-7.60 (m, 3H),
8.06 (s, 1H); LC/MS (ESI) m/z: 429.2 [M+H].sup.+.
(5R)-1-(1H-benzimidazol-5-yl)-5-{4-[5-(trifluoromethyl)thiophen-3-yl]pheny-
l}imidazolidin-2-one (Compound 35)
##STR00282##
[0309]
(5S)-1-(1H-benzimidazol-5-yl)-5-{4-[5-(trifluoromethyl)thiophen-3-y-
l]phenyl}imidazolidin-2-one (Compound 36)
##STR00283##
[0311] The enantiomers (Compounds 35 and 36) were separated from
Compound 16 by HPLC using CHIRALPAK AD-H. The isomer fractions were
respectively collected and the optical pure isomers (Compounds 35
and 36) were thus obtained by removing the solvent under reduced
pressure. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.36 (dd, 1H,
J=6.9, 9.0 Hz), 3.99 (dd, 1H, J=9.0, 9.3 Hz), 5.50 (dd, 1H, J=6.9,
9.3 Hz), 7.30 (d, 1H, J=8.1 Hz), 7.41-7.47 (m, 3H), 7.56-7.58 (m,
3H), 7.81 (s, 2H), 8.05 (s, 1H); LC/MS (ESI) m/z: 429.1
[M+H].sup.+.
1-{4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl}ethanone
(Compound 185)
##STR00284##
[0313] The
1-{4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl}ethanone 185 was
prepared from the Suzuki-coupling of (4-acetylphenyl)boronic acid
184 and Compound 119d. The procedures were the same as the
synthesis of Compound 120a. The product 185 was obtained as a white
solid at a yield of 83%. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
2.65 (s, 3H), 7.82 (s, 1H), 8.05 (d, 2H, J=8.6 Hz), 8.09 (d, 2H,
J=8.6 Hz); LC/MS (ESI) m/z: 271.7 [M+H].sup.+.
oxo{4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl}acetaldehyde
(Compound 186)
##STR00285##
[0315] The Compound 185 (10.0 g, 36.86 mmol) and selenium dioxide
(6.95 g, 62.67 mmol) were dissolved in H.sub.2O/1,4-dioxane (8
mL/160 mL). The reaction mixture was stirred at 100.degree. C.
overnight. The black solid was filtered through celite and washed
with ethyl acetate. The filtrate was concentrated under the reduced
pressure. The residue was purified by column chromatography on
silica gel using ethyl acetate/hexane (1/1) as eluent. The product
186 was obtained as a yellow solid at a yield of 100%.
1-(1H-benzimidazol-5-yl)-5-{4-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl-
}imidazolidine-2,4-dione (Compound 37)
##STR00286##
[0317] The Compound 186 (9.0 g, 31.55 mmol) and
1-(1H-benzimidazol-6-yl)urea 187 (5.56 g, 31.55 mmol) were
dissolved in HCl/AcOH (3 mL/120 mL). The reaction mixture was
stirred at 120.degree. C. overnight. After removing the solvents,
the residue was treated with the excess ammonia in methanol at an
ice-bath and stirred at room temperature for an hour. The
precipitates were filtered and washed with ethyl acetate and water
to get the pure product. The filtrate was concentrated and
recrystallized in ethyl acetate. The white solids were collected as
the product (Compound 37) at a yield of 45%. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 6.13 (s, 1H), 7.27 (s, 1H), 7.43 (s, 1H),
7.55 (d, 2H, J=8.4 Hz), 7.71 (s, 1H), 7.94 (d, 2H, J=8.4 Hz), 8.16
(s, 1H), 8.52 (s, 1H), 11.43 (s, 1H), 12.41 (s, 1H); LC/MS (ESI)
m/z: 444.2 [M+H].sup.+.
1-[4-(2-cyclopropyl-1,3-thiazol-4-yl)phenyl]ethanone (Compound
188)
##STR00287##
[0319] The 1-[4-(2-cyclopropyl-1,3-thiazol-4-yl)phenyl]ethanone 188
was prepared from the Suzuki-coupling of (4-acetylphenyl)boronic
acid 184 and Compound 126 with Pd(dppf)Cl.sub.2 as catalyst. The
procedures were the same as the synthesis of Compound 127. The
product 188 was obtained as a white solid at a yield of 57%.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 1.09-1.16 (m, 4H),
2.32-2.37 (m, 1H), 2.60 (s, 3H), 7.35 (s, 1H), 7.94 (d, 2H, J=8.8
Hz), 7.97 (d, 2H, J=8.8 Hz); LC/MS (ESI) m/z: 244.1
[M+H].sup.+.
[4-(2-cyclopropyl-1,3-thiazol-4-yl)phenyl](oxo)acetaldehyde
(Compound 189)
##STR00288##
[0321] The
[4-(2-cyclopropyl-1,3-thiazol-4-yl)phenyl](oxo)acetaldehyde 189 was
prepared from the oxidation of Compound 188 by selenium dioxide.
The procedures were the same as the synthesis of Compound 186. The
product 189 was obtained as a yellow solid at a yield of 100%.
1-(1H-benzimidazol-5-yl)-5-[4-(2-cyclopropyl-1,3-thiazol-4-yl)phenyl]imida-
zolidine-2,4-dione (Compound 38)
##STR00289##
[0323] The
1-(1H-benzimidazol-5-yl)-5-[4-(2-cyclopropyl-1,3-thiazol-4-yl)p-
henyl]-imidazolidine-2,4-dione (Compound 38) was prepared from the
cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound 189.
The procedures were the same as the synthesis of Compound 37. The
product (Compound 38) was obtained as a white solid at a yield of
49%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.00-1.03 (m, 2H),
1.08-1.11 (m, 2H), 2.36-2.42 (m, 1H), 6.03 (s, 1H), 7.28 (s, 1H),
7.41 (d, 2H, J=8.0 Hz), 7.48 (s, 1H), 7.69 (s, 1H), 7.77 (s, 1H),
7.83 (d, 2H, J=8.0 Hz), 8.15 (s, 1H), 11.38 (s, 1H), 12.41 (s, 1H);
LC/MS (ESI) m/z: 416.2 [M+H].sup.+.
1-[4-(2-cyclopropyl-1,3-thiazol-5-yl)phenyl]ethanone (Compound
190b)
##STR00290##
[0325] To the solution of Compound 134b (0.23 g, 1.0 mmol) in
anhydrous THF (4 mL), the methylmagnesium bromide in THF (1M, 2 mL)
was added dropwise at 0.degree. C. Then, the reaction mixture was
stirred at room temperature overnight. The saturated aqueous
solution of ammonium chloride was added to quench the reaction. The
aqueous layer was extracted with ethyl acetate. The organic layers
were collected, washed with brine, dried over sodium sulfate,
filtered and concentrated under reduced pressure. The residue was
purified by column chromatography on silica gel using ethyl
acetate/hexane (1/4) as eluent. The product 190b was obtained as a
yellow solid at a yield of 48%. .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 1.13-1.19 (m, 4H), 2.30-2.35 (m, 1H), 2.61 (s, 3H), 7.58
(d, 2H, J=8.0 Hz), 7.85 (s, 1H), 7.96 (d, 2H, J=8.0 Hz); LC/MS
(ESI) m/z: 244.1 [M+H].sup.+.
1-{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl}ethanone
(Compound 190c)
##STR00291##
[0327] The
1-{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl}ethanone 190c was
prepared from the methylation of Compound 134c. The procedures were
the same as the synthesis of Compound 190b. The product 190c was
obtained as a yellow solid at a yield of 49%. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 2.64 (s, 3H), 7.69 (d, 2H, J=8.0 Hz), 8.04 (d,
2H, J=8.0 Hz), 8.17 (s, 1H); LC/MS (ESI) m/z: 271.7 [M+H]+.
[4-(2-cyclopropyl-1,3-thiazol-5-yl)phenyl](oxo)acetaldehyde
(Compound 191b)
##STR00292##
[0329] The
[4-(2-cyclopropyl-1,3-thiazol-5-yl)phenyl](oxo)acetaldehyde 191b
was prepared from the oxidation of Compound 190b by selenium
dioxide. The procedures were the same as the synthesis of Compound
186. The product 191b was obtained as a yellow solid at a yield of
100%.
oxo{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl}acetaldehyde
(Compound 191c)
##STR00293##
[0331] The
oxo{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl}acetaldehyde
191c was prepared from the oxidation of Compound 190c by selenium
dioxide. The procedures were the same as the synthesis of Compound
186. The product 191c was obtained as a yellow solid at a yield of
100%.
1-(1H-benzimidazol-5-yl)-5-[4-(2-cyclopropyl-1,3-thiazol-5-yl)phenyl]imida-
zolidine-2,4-dione (Compound 39)
##STR00294##
[0333] The
1-(1H-benzimidazol-5-yl)-5-[4-(2-cyclopropyl-1,3-thiazol-5-yl)p-
henyl]-imidazolidine-2,4-dione (Compound 39) was prepared from the
cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
191b. The procedures were the same as the synthesis of Compound 37.
The product (Compound 39) was obtained as a white solid at a yield
of 57%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 0.93-0.99 (m,
2H), 1.01-1.11 (m, 2H), 2.33-2.39 (m, 1H), 6.05 (s, 1H), 7.33 (d,
1H, J=8.6 Hz), 7.41 (d, 2H, J=8.0 Hz), 7.48 (d, 1H, J=8.6 Hz), 7.53
(d, 2H, J=8.0 Hz), 7.70 (d, 1H, J=1.2 Hz), 7.91 (s, 1H), 8.18 (s,
1H), 11.39 (s, 1H), 12.47 (s, 1H); LC/MS (ESI) m/z: 416.2
[M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl-
}imidazolidine-2,4-dione (Compound 40)
##STR00295##
[0335] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(trifluoromethyl)-1,3-thiazol--
5-yl]phenyl}-imidazolidine-2,4-dione (Compound 40) was prepared
from the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and
Compound 191c. The procedures were the same as the synthesis of
Compound 37. The product (Compound 40) was obtained as a white
solid at a yield of 30%. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 6.12 (s, 1H), 7.35 (s, 1H), 7.47-7.52 (m, 3H), 7.71-7.75
(m, 3H), 8.16 (s, 1H), 8.48 (s, 1H), 11.44 (s, 1H), 12.43 (s, 1H);
LC/MS (ESI) m/z: 444.2 [M+H]+.
1-[4-(2H-tetrazol-5-yl)phenyl]ethanone (Compound 192)
##STR00296##
[0337] To the solution of 4-acetylbenzonitrile 143 (4.35 g, 30.0
mmol) in DMF (30 mL), sodium azide (2.15 g, 33 mmol) and ammonium
chloride (0.40 g, 7.5 mmol) were added under nitrogen. The reaction
mixture was refluxed overnight and then cooled to room temperature.
The reaction mixture was diluted with water and extracted with DCM.
The aqueous phase was chilled in ice and acidified by adding 1N
HCl.sub.(aq). After filtering, the precipitates were washed with
water and ether to obtain the product 192 as a yellow solid at a
yield of 94%.
1-(1H-benzimidazol-5-yl)-5-[4-(2-methyl-2H-tetrazol-5-yl)phenyl]imidazolid-
ine-2,4-dione (Compound 41)
##STR00297##
[0339] The
1-(1H-benzimidazol-5-yl)-5-[4-(2-methyl-2H-tetrazol-5-yl)phenyl-
]imidazolidine-2,4-dione (Compound 41) was prepared from the
cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
194a. The procedures were the same as the synthesis of Compound 37.
The product (Compound 41) was obtained as a white solid at a yield
of 17%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.38 (s, 3H),
6.12 (s, 1H), 7.28 (br s, 1H), 7.47 (br s, 1H), 7.57 (d, 2H, J=8.4
Hz), 7.72 (s, 1H), 8.00 (d, 2H, J=8.4 Hz), 8.16 (s, 1H), 11.46 (br
s, 1H), 12.44 (br s, 1H); LC/MS (ESI) m/z: 375.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-[4-(2-propyl-2H-tetrazol-5-yl)phenyl]imidazolid-
ine-2,4-dione (Compound 42)
##STR00298##
[0341] The
1-(1H-benzimidazol-5-yl)-5-[4-(2-propyl-2H-tetrazol-5-yl)phenyl-
]imidazolidine-2,4-dione (Compound 42) was prepared from the
cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
194b. The procedures were the same as the synthesis of Compound 37.
The product (Compound 42) was obtained as a white solid at a yield
of 33%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 0.84 (t, 3H,
J=7.5 Hz), 1.87-1.99 (m, 2H), 4.65 (t, 2H, J=6.8 Hz), 6.12 (s, 1H),
7.34 (br s, 1H), 7.47 (br s, 1H), 7.57 (d, 2H, J=8.4 Hz), 7.71 (s,
1H), 8.00 (d, 2H, J=8.4 Hz), 8.15 (s, 1H), 11.43 (s, 1H), 12.41 (s,
1H); LC/MS (ESI) m/z: 403.2 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(propan-2-yl)-2H-tetrazol-5-yl]phenyl}imi-
dazolidine-2,4-dione (Compound 43)
##STR00299##
[0343] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(propan-2-yl)-2H-tetrazol-5-yl-
]phenyl}-imidazolidine-2,4-dione (Compound 43) was prepared from
the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
194c. The procedures were the same as the synthesis of Compound 37.
The product (Compound 43) was obtained as a white solid at a yield
of 28%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.57 (d, 6H,
J=6.4 Hz), 5.09-5.16 (m, 1H), 6.11 (s, 1H), 7.27 (br s, 1H), 7.42
(br s, 1H), 7.57 (d, 2H, J=8.4 Hz), 7.71 (s, 1H), 8.00 (d, 2H,
J=8.4 Hz), 8.15 (s, 1H), 11.43 (s, 1H), 12.41 (s, 1H); LC/MS (ESI)
m/z: 403.2 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(2-methylpropyl)-2H-tetrazol-5-yl]phenyl}-
imidazolidine-2,4-dione (Compound 44)
##STR00300##
[0345] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(2-methylpropyl)-2H-tetrazol-5-
-yl]phenyl}-imidazolidine-2,4-dione (Compound 44) was prepared from
the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
194d. The procedures were the same as the synthesis of Compound 37.
The product (Compound 44) was obtained as a white solid at a yield
of 34%. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 0.86 (d, 6H,
J=6.4 Hz), 2.22-2.29 (m, 1H), 4.53 (d, 2H, J=6.8 Hz), 6.12 (s, 1H),
7.28 (br s, 1H), 7.47 (br s, 1H), 7.57 (d, 2H, J=8.0 Hz), 7.72 (s,
1H), 8.01 (d, 2H, J=8.0 Hz), 8.16 (s, 1H), 11.45 (s, 1H), 12.42 (s,
1H); LC/MS (ESI) m/z: 417.2 [M+H]+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(cyclopropylmethyl)-2H-tetrazol-5-yl]phen-
yl}-imidazolidine-2,4-dione (Compound 45)
##STR00301##
[0347] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(cyclopropylmethyl)-2H-tetrazo-
l-5-yl]phenyl}-imidazolidine-2,4-dione (Compound 45) was prepared
from the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and
Compound 194e. The procedures were the same as the synthesis of
Compound 37. The product (Compound 45) was obtained as a white
solid at a yield of 31%. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 0.42-0.45 (m, 2H), 0.54-0.58 (m, 2H), 1.33-1.41 (m, 1H),
4.57 (d, 2H, J=7.2 Hz), 6.12 (s, 1H), 7.29 (br s, 1H), 7.46 (br s,
1H), 7.58 (d, 2H, J=8.4 Hz), 7.72 (s, 1H), 8.01 (d, 2H, J=8.4 Hz),
8.15 (s, 1H), 11.43 (s, 1H), 12.41 (s, 1H); LC/MS (ESI) m/z: 415.1
[M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(2,2,2-trifluoroethyl)-2H-tetrazol-5-yl]p-
henyl}-imidazolidine-2,4-dione (Compound 46)
##STR00302##
[0349] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(2,2,2-trifluoroethyl)-2H-tetr-
azol-5-yl]phenyl}-imidazolidine-2,4-dione (Compound 46) was
prepared from the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187
and Compound 194f. The procedures were the same as the synthesis of
Compound 37. The product (Compound 46) was obtained as a white
solid at a yield of 36%. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 6.01 (q, 2H, J=8.7 Hz), 6.15 (s, 1H), 7.36 (br s, 1H), 7.48
(br s, 1H), 7.61 (d, 2H, J=8.4 Hz), 7.73 (s, 1H), 8.04 (d, 2H,
J=8.4 Hz), 8.17 (s, 1H), 11.49 (br s, 1H), 12.41 (br s, 1H); LC/MS
(ESI) m/z: 443.2 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(prop-2-yn-1-yl)-2H-tetrazol-5-yl]phenyl}-
imidazolidine-2,4-dione (Compound 47)
##STR00303##
[0351] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(prop-2-yn-1-yl)-2H-tetrazol-5-
-yl]phenyl}-imidazolidine-2,4-dione (Compound 47) was prepared from
the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
194g. The procedures were the same as the synthesis of Compound 37.
The product (Compound 47) was obtained as a white solid at a yield
of 36%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 5.75 (d, 1H,
J=1.5 Hz), 6.07 (d, 1H, J=6.6 Hz), 6.14 (s, 1H), 7.29 (br s, 1H),
7.47 (br s, 1H), 7.59 (d, 2H, J=8.0 Hz), 7.72 (s, 1H), 8.02 (d, 2H,
J=8.0 Hz), 8.16 (s, 1H), 8.24 (dd, 1H, J=1.5, 6.6 Hz), 11.47 (br s,
1H), 12.44 (s, 1H); LC/MS (ESI) m/z: 399.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(but-2-yn-1-yl)-2H-tetrazol-5-yl]phenyl}i-
midazolidine-2,4-dione (Compound 48)
##STR00304##
[0353] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(but-2-yn-1-yl)-2H-tetrazol-5--
yl]phenyl}-imidazolidine-2,4-dione (Compound 48) was prepared from
the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
194h. The procedures were the same as the synthesis of Compound 37.
The product (Compound 48) was obtained as a white solid at a yield
of 34%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.83 (s, 3H),
5.65 (d, 2H, J=1.8 Hz), 6.13 (s, 1H), 7.34 (d, 1H, J=6.6 Hz), 7.48
(d, 1H, J=8.7 Hz), 7.58 (d, 2H, J=7.8 Hz), 7.72 (s, 1H), 8.02 (d,
2H, J=7.8 Hz), 8.16 (s, 1H), 11.44 (s, 1H), 12.41 (s, 1H); LC/MS
(ESI) m/z: 413.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(pent-2-yn-1-yl)-2H-tetrazol-5-yl]phenyl}-
imidazolidine-2,4-dione (Compound 49)
##STR00305##
[0355] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(pent-2-yn-1-yl)-2H-tetrazol-5-
-yl]phenyl}-imidazolidine-2,4-dione (Compound 49) was prepared from
the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
194i. The procedures were the same as the synthesis of Compound 37.
The product (Compound 49) was obtained as a white solid at a yield
of 32%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 1.03 (t, 3H,
J=7.5 Hz), 2.17-2.26 (m, 2H), 5.65 (t, 2H, J=2.1 Hz), 6.11 (s, 1H),
7.29 (br s, 1H), 7.46 (br s, 1H), 7.58 (d, 2H, J=8.4 Hz), 7.71 (s,
1H), 8.01 (d, 2H, J=8.4 Hz), 8.15 (s, 1H), 11.43 (br s, 1H), 12.42
(br s, 1H); LC/MS (ESI) m/z: 427.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(4-chlorobenzyl)-2H-tetrazol-5-yl]phenyl}-
imidazolidine-2,4-dione (Compound 50)
##STR00306##
[0357] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(4-chlorobenzyl)-2H-tetrazol-5-
-yl]phenyl}-imidazolidine-2,4-dione (Compound 50) was prepared from
the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and Compound
194j. The procedures were the same as the synthesis of Compound 37.
The product (Compound 50) was obtained as a white solid at a yield
of 43%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 5.98 (s, 2H),
6.11 (s, 1H), 7.25 (d, 1H, J=8.1 Hz), 7.36-7.50 (m, 5H), 7.56 (d,
2H, J=8.4 Hz), 7.70 (s, 1H), 7.99 (d, 2H, J=8.4 Hz), 8.15 (s, 1H),
11.44 (s, 1H), 12.41 (s, 1H); LC/MS (ESI) m/z: 485.1
[M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(4-methoxybenzyl)-2H-tetrazol-5-yl]phenyl-
}-imidazolidine-2,4-dione (Compound 51)
##STR00307##
[0359] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(4-methoxybenzyl)-2H-tetrazol--
5-yl]phenyl}-imidazolidine-2,4-dione (Compound 51) was prepared
from the cycloaddition of 1-(1H-benzimidazol-6-yl)urea 187 and
Compound 194k. The procedures were the same as the synthesis of
Compound 37. The product (Compound 51) was obtained as a white
solid at a yield of 22%. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 3.71 (s, 3H), 5.86 (s, 2H), 6.15 (s, 1H), 6.91 (d, 2H,
J=8.4 Hz), 7.33 (d, 2H, J=8.4 Hz), 7.42 (br s, 2H), 7.55 (d, 2H,
J=8.1 Hz), 7.70 (s, 1H), 7.98 (d, 2H, J=8.1 Hz), 8.15 (s, 1H),
11.43 (s, 1H), 12.41 (s, 1H); LC/MS (ESI) m/z: 481.2 [M+H]+.
1-(1H-benzimidazol-5-yl)-5-(4-{2-[(3-methyl-1,2-oxazol-5-yl)methyl]-2H-tet-
razol-5-yl}phenyl)imidazolidine-2,4-dione (Compound 52)
##STR00308##
[0361] The
1-(1H-benzimidazol-5-yl)-5-(4-{2-[(3-methyl-1,2-oxazol-5-yl)met-
hyl]-2H-tetrazol-5-yl}phenyl)imidazolidine-2,4-dione (Compound 52)
was prepared from the cycloaddition of 1-(1H-benzimidazol-6-yl)urea
187 and Compound 194l. The procedures were the same as the
synthesis of Compound 37. The product (Compound 52) was obtained as
a white solid at a yield of 52%. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 2.20 (s, 3H), 6.12 (s, 1H), 6.24 (s, 2H),
6.51 (s, 1H), 7.27 (br s, 1H), 7.46 (br s, 1H), 7.58 (d, 2H, J=8.0
Hz), 7.71 (s, 1H), 8.00 (d, 2H, J=8.0 Hz), 8.16 (s, 1H), 11.30 (br
s, 1H), 12.42 (br s, 1H); LC/MS (ESI) m/z: 456.1 [M+H].sup.+.
N-[2-(4-cyanophenyl)-2-oxoethyl]tricyclo[3.3.1.1.sup.3,7]decane-1-carboxam-
ide (Compound 196)
##STR00309##
[0363] The
N-[2-(4-cyanophenyl)-2-oxoethyl]tricyclo[3.3.1.1.sup.3,7]decane-
-1-carboxamide 196 was prepared through the acetylation of compound
131 with adamantane-1-carbonyl chloride 195. The experimental
procedures were the same as the synthesis of compound 133a. The
product 196 was obtained as a yellow solid at a yield of 53%.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 1.71-1.78 (m, 6H), 1.92
(s, 6H), 2.07 (s, 3H), 4.74 (d, 2H, J=4.0 Hz), 6.65 (s, 1H), 7.81
(d, 2H, J=8.6 Hz), 8.07 (d, 2H, J=8.6 Hz); LC/MS (ESI) m/z: 323.3
[M+H].sup.+.
4-[2-(tricyclo[3.3.1.1.sup.3,7]dec-1-yl)-1,3-thiazol-5-yl]benzonitrile
(Compound 197)
##STR00310##
[0365] The
4-[2-(tricyclo[3.3.1.1.sup.3'7]dec-1-yl)-1,3-thiazol-5-yl]benzo-
nitrile 197 was prepared from the cyclization of compound 196 with
the Lawesson's reagent in THF. The experimental procedures were the
same as the synthesis of compound 134a. The product 197 was
obtained as a white solid at a yield of 49%. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 1.80 (s, 6H), 2.08 (s, 6H), 2.13 (s, 3H),
7.61-7.67 (m, 4H), 7.94 (s, 1H); LC/MS (ESI) m/z: 321.3 [M+H]+.
4-[2-(tricyclo[3.3.1.1.sup.3,7]dec-1-yl)-1,3-thiazol-5-yl]benzaldehyde
(Compound 198)
##STR00311##
[0367] The
4-[2-(tricyclo[3.3.1.1.sup.3'7]dec-1-yl)-1,3-thiazol-5-yl]benza-
ldehyde 198 was prepared from the reduction of compound 197 with
the DIBAL-H reagent. The experimental procedures were the same as
the synthesis of compound 135a. The product 198 was obtained as a
yellow solid at a yield of 83%. .sup.1H NMR (300 MHz, CDCl.sub.3)
.delta. 1.81 (s, 6H), 2.10 (s, 6H), 2.14 (s, 3H), 7.70 (d, 2H,
J=8.4 Hz), 7.89 (d, 2H, J=8.4 Hz), 7.98 (s, 1H), 10.00 (s, 1H);
LC/MS (ESI) m/z: 324.3 [M+H].sup.+.
(1H-benzimidazol-5-ylamino){4-[2-(tricyclo[3.3.1.1.sup.3,7]dec-1-yl)-1,3-t-
hiazol-5-yl]phenyl}acetonitrile (Compound 199)
##STR00312##
[0369] The (1H-benzimidazol-5-ylamino)
{4-[2-(tricyclo[3.3.1.1.sup.3'7]dec-1-yl)-1,3-thiazol-5-yl]phenyl}acetoni-
trile 199 was prepared from the addition of 1H-benzimidazol-5-amine
121, TMSCN and compound 198. The experimental procedures were the
same as the synthesis of compound 122a. The product 199 was
obtained as a pale-yellow solid at a yield of 91%.
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[2-(tricyclo[3.3.1.1.sup.3'7]dec-1-yl)-
-1,3-thiazol-5-yl]phenyl}ethane-1,2-diamine (Compound 200)
##STR00313##
[0371] The
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[2-(tricyclo[3.3.1.1.sup.3,-
7]dec-1-yl)-1,3-thiazol-5-yl]phenyl}ethane-1,2-diamine 200 was
prepared from the hydrogenation of compound 199 with the Raney
Nickel reagent as catalyst. The experimental procedures were the
same as the synthesis of compound 123a. The product 200 was
obtained as a yellow viscous liquid at a yield of 60%.
1-(1H-benzimidazol-5-yl)-5-{4-[2-(tricyclo[3.3.1.1.sup.3'7]dec-1-yl)-1,3-t-
hiazol-5-yl]phenyl}imidazolidin-2-one (Compound 57)
##STR00314##
[0373] The
1-(1H-benzimidazol-5-yl)-5-{4-[2-(tricyclo[3.3.1.1.sup.3'7]dec--
1-yl)-1,3-thiazol-5-yl]phenyl}imidazolidin-2-one (Compound 57) was
prepared from the cycloaddition of 1,1'-carbonyl diimidazole and
compound 200. The experimental procedures were the same as the
synthesis of Compound 1. The product (Compound 57) was obtained as
a yellow solid at a yield of 78%. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 1.75 (s, 6H), 2.03 (s, 6H), 2.05 (s, 3H), 3.32-3.36 (m,
1H), 3.97 (dd, 1H, J=9.2, 9.2 Hz), 5.49 (dd, 1H, J=6.8, 9.2 Hz),
7.30 (d, 1H, J=8.8 Hz), 7.40 (d, 2H, J=8.4 Hz), 7.45-7.49 (m, 3H),
7.56 (s, 1H), 7.79 (s, 1H), 8.06 (s, 1H); LC/MS (ESI) m/z: 496.4
[M+H].sup.+.
2,3-difluoro-4-(5-fluorothiophen-3-yl)benzaldehyde (Compound
201a)
##STR00315##
[0375] The 2,3-difluoro-4-(5-fluorothiophen-3-yl)benzaldehyde 201a
was prepared from the Suzuki-Miyaura coupling of
2,3-difluoro-4-formylphenylboronic acid 118g and
4-bromo-2-fluorothiophene 158d. The experimental procedures were
the same as the synthesis of compound 159a. The product 201a was
obtained as a pale-yellow oil at a yield of 42%.
4-(5-chlorothiophen-3-yl)-2,3-difluorobenzaldehyde (Compound
201b)
##STR00316##
[0377] The 4-(5-chlorothiophen-3-yl)-2,3-difluorobenzaldehyde 201b
was prepared from the Suzuki-Miyaura coupling of
2,3-difluoro-4-formylphenylboronic acid 118g and
4-bromo-2-chlorothiophene 158e. The experimental procedures were
the same as the synthesis of compound 159a. The product 201b was
obtained as a pale-yellow oil at a yield of 45%.
2,3-difluoro-4-(5-methylthiophen-3-yl)benzaldehyde (Compound
201c)
##STR00317##
[0379] The 2,3-difluoro-4-(5-methylthiophen-3-yl)benzaldehyde 201c
was prepared from the Suzuki-Miyaura coupling of
2,3-difluoro-4-formylphenylboronic acid 118g and
4-bromo-2-methylthiophene 158b. The experimental procedures were
the same as the synthesis of compound 159a. The product 201c was
obtained as a pale-yellow oil at a yield of 53%.
4-(5-ethylthiophen-3-yl)-2,3-difluorobenzaldehyde (Compound
201d)
##STR00318##
[0381] The 4-(5-ethylthiophen-3-yl)-2,3-difluorobenzaldehyde 201d
was prepared from the Suzuki-Miyaura coupling of
2,3-difluoro-4-formylphenylboronic acid 118g and
4-bromo-2-ethylthiophene 158f. The experimental procedures were the
same as the synthesis of compound 159a. The product 201d was
obtained as a pale-yellow oil at a yield of 56%.
2,3-difluoro-4-[5-(methoxymethyl)thiophen-3-yl]benzaldehyde
(Compound 201e)
##STR00319##
[0383] The
2,3-difluoro-4-[5-(methoxymethyl)thiophen-3-yl]benzaldehyde 201e
was prepared from the Suzuki-Miyaura coupling of
2,3-difluoro-4-formylphenylboronic acid 118g and
4-bromo-2-(methoxymethyl)thiophene 158g. The experimental
procedures were the same as the synthesis of compound 159a. The
product 201e was obtained as a pale-yellow oil at a yield of
49%.
4-[5-(ethoxymethyl)thiophen-3-yl]-2,3-difluorobenzaldehyde
(Compound 201f)
##STR00320##
[0385] The
4-[5-(ethoxymethyl)thiophen-3-yl]-2,3-difluorobenzaldehyde 201f was
prepared from the Suzuki-Miyaura coupling of
2,3-difluoro-4-formylphenylboronic acid 118g and
4-bromo-2-(ethoxymethyl)thiophene 158h. The experimental procedures
were the same as the synthesis of compound 159a. The product 201f
was obtained as a pale-yellow oil at a yield of 48%.
methyl 4-(2,3-difluoro-4-formylphenyl)thiophene-2-carboxylate
(Compound 201g)
##STR00321##
[0387] The methyl
4-(2,3-difluoro-4-formylphenyl)thiophene-2-carboxylate 201g was
prepared from the Suzuki-Miyaura coupling of
2,3-difluoro-4-formylphenylboronic acid 118g and methyl
4-bromothiophene-2-carboxylate 158i. The experimental procedures
were the same as the synthesis of compound 159a. The product 201g
was obtained as a pale-yellow oil at a yield of 42%.
2,3-difluoro-4-(thiophen-3-yl)benzaldehyde (Compound 201h)
##STR00322##
[0389] The 2,3-difluoro-4-(thiophen-3-yl)benzaldehyde 201h was
prepared from the Suzuki-Miyaura coupling of
2,3-difluoro-4-formylphenylboronic acid 118g and 3-bromothiophene
158a. The experimental procedures were the same as the synthesis of
compound 159a. The product 201h was obtained as a pale-yellow oil
at a yield of 54%.
(1H-benzimidazol-5-ylamino)
[2,3-difluoro-4-(5-fluorothiophen-3-yl)phenyl]acetonitrile
(Compound 202a)
##STR00323##
[0391] The
(1H-benzimidazol-5-ylamino)[2,3-difluoro-4-(5-fluorothiophen-3--
yl)phenyl]-acetonitrile 202a was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and compound 201a. The
experimental procedures were the same as the synthesis of compound
122a. The product 202a was obtained as a pale-yellow solid at a
yield of 85%.
(1H-benzimidazol-5-ylamino)
[4-(5-chlorothiophen-3-yl)-2,3-difluorophenyl]acetonitrile
(Compound 202b)
##STR00324##
[0393] The
(1H-benzimidazol-5-ylamino)[4-(5-chlorothiophen-3-yl)-2,3-diflu-
orophenyl]acetonitrile 202b was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and compound 201b. The
experimental procedures were the same as the synthesis of compound
122a. The product 202b was obtained as a pale-yellow solid at a
yield of 79%.
(1H-benzimidazol-5-ylamino)
[2,3-difluoro-4-(5-methylthiophen-3-yl)phenyl]acetonitrile
(Compound 202c)
##STR00325##
[0395] The
(1H-benzimidazol-5-ylamino)[2,3-difluoro-4-(5-methylthiophen-3--
yl)phenyl]acetonitrile 202c was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and compound 201c. The
experimental procedures were the same as the synthesis of compound
122a. The product 202c was obtained as a pale-yellow solid at a
yield of 88%.
(1H-benzimidazol-5-ylamino)
[4-(5-ethylthiophen-3-yl)-2,3-difluorophenyl]acetonitrile (Compound
202d)
##STR00326##
[0397] The
(1H-benzimidazol-5-ylamino)[4-(5-ethylthiophen-3-yl)-2,3-difluo-
rophenyl]-acetonitrile 202d was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and compound 201d. The
experimental procedures were the same as the synthesis of compound
122a. The product 202d was obtained as a pale-yellow solid at a
yield of 81%.
(1H-benzimidazol-5-ylamino){2,3-difluoro-4-[5-(methoxymethyl)thiophen-3-yl-
]phenyl}acetonitrile (Compound 202e)
##STR00327##
[0399] The (1H-benzimidazol-5-ylamino)
{2,3-difluoro-4-[5-(methoxymethyl)thiophen-3-yl]phenyl}acetonitrile
202e was prepared from the addition of 1H-benzimidazol-5-amine 121,
TMSCN and compound 201e. The experimental procedures were the same
as the synthesis of compound 122a. The product 202e was obtained as
a pale-yellow solid at a yield of 84%.
(1H-benzimidazol-5-ylamino){4-[5-(ethoxymethyl)thiophen-3-yl]-2,3-difluoro-
phenyl}acetonitrile (Compound 202f)
##STR00328##
[0401] The (1H-benzimidazol-5-ylamino)
{4-[5-(ethoxymethyl)thiophen-3-yl]-2,3-difluorophenyl}acetonitrile
202f was prepared from the addition of 1H-benzimidazol-5-amine 121,
TMSCN and compound 201f. The experimental procedures were the same
as the synthesis of compound 122a. The product 202f was obtained as
a pale-yellow solid at a yield of 90%.
Methyl
4-{4-[(1H-benzimidazol-5-ylamino)(cyano)methyl]-2,3-difluorophenyl}-
thiophene-2-carboxylate (Compound 202g)
##STR00329##
[0403] The methyl
4-{4-[(1H-benzimidazol-5-ylamino)(cyano)methyl]-2,3-difluorophenyl}thioph-
ene-2-carboxylate 202g was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and compound 201g. The
experimental procedures were the same as the synthesis of compound
122a. The product 202g was obtained as a pale-yellow solid at a
yield of 81%.
(1H-benzimidazol-5-ylamino)
[2,3-difluoro-4-(thiophen-3-yl)phenyl]acetonitrile (Compound
202h)
##STR00330##
[0405] The
(1H-benzimidazol-5-ylamino)[2,3-difluoro-4-(thiophen-3-yl)pheny-
l]acetonitrile 202h was prepared from the addition of
1H-benzimidazol-5-amine 121, TMSCN and compound 201h. The
experimental procedures were the same as the synthesis of compound
122a. The product 202h was obtained as a pale-yellow solid at a
yield of 92%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[2,3-difluoro-4-(5-fluorothiophen-3-yl)ph-
enyl]ethane-1,2-diamine (Compound 203a)
##STR00331##
[0407] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[2,3-difluoro-4-(5-fluorothiop-
hen-3-yl)phenyl]ethane-1,2-diamine 203a was prepared from the
hydrogenation of compound 202a with the Raney Nickel reagent as
catalyst. The experimental procedures were the same as the
synthesis of compound 123a. The product 203a was obtained as a
yellow viscous liquid at a yield of 43%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-chlorothiophen-3-yl)-2,3-difluoroph-
enyl]ethane-1,2-diamine (Compound 203b)
##STR00332##
[0409] The
N-(1H-benzimidazol-5-yl)-1-[4-(5-chlorothiophen-3-yl)-2,3-diflu-
orophenyl]ethane-1,2-diamine 203b was prepared from the
hydrogenation of compound 202b with the Raney Nickel reagent as
catalyst. The experimental procedures were the same as the
synthesis of compound 123a. The product 203b was obtained as a
yellow viscous liquid at a yield of 40%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[2,3-difluoro-4-(5-methylthiophen-3-yl)ph-
enyl]ethane-1,2-diamine (Compound 203c)
##STR00333##
[0411] The
N-(1H-benzimidazol-5-yl)-1-[2,3-difluoro-4-(5-methylthiophen-3--
yl)phenyl]ethane-1,2-diamine 203c was prepared from the
hydrogenation of compound 202c with the Raney Nickel reagent as
catalyst. The experimental procedures were the same as the
synthesis of compound 123a. The product 203c was obtained as a
yellow viscous liquid at a yield of 53%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-ethylthiophen-3-yl)-2,3-difluorophe-
nyl]ethane-1,2-diamine (Compound 203d)
##STR00334##
[0413] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[4-(5-ethylthiophen-3-yl)-2,3--
difluorophenyl]ethane-1,2-diamine 203d was prepared from the
hydrogenation of compound 202d with the Raney Nickel reagent as
catalyst. The experimental procedures were the same as the
synthesis of compound 123a. The product 203d was obtained as a
yellow viscous liquid at a yield of 51%.
N.sup.1-(1H-benzimidazol-5-yl)-1-{2,3-difluoro-4-[5-(methoxymethyl)thiophe-
n-3-yl]phenyl}ethane-1,2-diamine (Compound 203e)
##STR00335##
[0415] The
N-(1H-benzimidazol-5-yl)-1-{2,3-difluoro-4-[5-(methoxymethyl)th-
iophen-3-yl]phenyl}ethane-1,2-diamine 203e was prepared from the
hydrogenation of compound 202e with the Raney Nickel reagent as
catalyst. The experimental procedures were the same as the
synthesis of compound 123a. The product 203e was obtained as a
yellow viscous liquid at a yield of 46%.
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[5-(ethoxymethyl)thiophen-3-yl]-2,3-di-
fluorophenyl}ethane-1,2-diamine (Compound 203f)
##STR00336##
[0417] The
N.sup.1-(1H-benzimidazol-5-yl)-1-{4-[5-(ethoxymethyl)thiophen-3-
-yl]-2,3-difluorophenyl}ethane-1,2-diamine 203f was prepared from
the hydrogenation of compound 202f with the Raney Nickel reagent as
catalyst. The experimental procedures were the same as the
synthesis of compound 123a. The product 203f was obtained as a
yellow viscous liquid at a yield of 49%.
methyl
4-{4-[2-amino-1-(1H-benzimidazol-5-ylamino)ethyl]-2,3-difluoropheny-
l}thiophene-2-carboxylate (Compound 203g)
##STR00337##
[0419] The methyl
4-{4-[2-amino-1-(1H-benzimidazol-5-ylamino)ethyl]-2,3-difluorophenyl}thio-
phene-2-carboxylate 203g was prepared from the hydrogenation of
compound 202g with the Raney Nickel reagent as catalyst. The
experimental procedures were the same as the synthesis of compound
123a. The product 203g was obtained as a yellow viscous liquid at a
yield of 47%.
N.sup.1-(1H-benzimidazol-5-yl)-1-[2,3-difluoro-4-(thiophen-3-yl)phenyl]eth-
ane-1,2-diamine (Compound 203h)
##STR00338##
[0421] The
N.sup.1-(1H-benzimidazol-5-yl)-1-[2,3-difluoro-4-(thiophen-3-yl-
)phenyl]ethane-1,2-diamine 203h was prepared from the hydrogenation
of compound 202h with the Raney Nickel reagent as catalyst. The
experimental procedures were the same as the synthesis of compound
123a. The product 203h was obtained as a yellow viscous liquid at a
yield of 58%.
1-(1H-benzimidazol-5-yl)-5-[2,3-difluoro-4-(5-fluorothiophen-3-yl)phenyl]i-
midazolidin-2-one (Compound 58)
##STR00339##
[0423] The
1-(1H-benzimidazol-5-yl)-5-[2,3-difluoro-4-(5-fluorothiophen-3--
yl)phenyl]imidazolidin-2-one (Compound 58) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and compound 203a. The
experimental procedures were the same as the synthesis of Compound
1. The product (Compound 58) was obtained as a white solid at a
yield of 71%.
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-3-yl)-2,3-difluorophenyl]i-
midazolidin-2-one (Compound 59)
##STR00340##
[0425] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-chlorothiophen-3-yl)-2,3-diflu-
orophenyl]imidazolidin-2-one (Compound 59) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and compound 203b. The
experimental procedures were the same as the synthesis of Compound
1. The product (Compound 59) was obtained as a white solid at a
yield of 74%. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 3.44 (dd,
1H, J=6.3, 9.3 Hz), 4.05 (dd, 1H, J=9.3, 9.6 Hz), 5.83 (dd, 1H,
J=6.3, 9.6 Hz), 7.17-7.34 (m, 4H), 7.48-7.51 (m, 2H), 7.60 (d, 1H,
J=1.8 Hz), 8.07 (d, 1H, J=3.9 Hz); LC/MS (ESI) m/z: 431.0
[M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-[2,3-difluoro-4-(5-methylthiophen-3-yl)phenyl]i-
midazolidin-2-one (Compound 60)
##STR00341##
[0427] The
1-(1H-benzimidazol-5-yl)-5-[2,3-difluoro-4-(5-methylthiophen-3--
yl)phenyl]imidazolidin-2-one (Compound 60) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and compound 203c. The
experimental procedures were the same as the synthesis of Compound
1. The product (Compound 60) was obtained as a white solid at a
yield of 70%. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 2.45 (s,
3H), 3.43 (dd, 1H, J=6.3, 9.0 Hz), 4.04 (dd, 1H, J=9.0, 9.3 Hz),
5.81 (dd, 1H, J=6.3, 9.3 Hz), 7.02 (s, 1H), 7.18-7.38 (m, 4H), 7.49
(d, 1H, J=8.4 Hz), 7.59 (s, 1H), 8.07 (s, 1H); LC/MS (ESI) m/z:
411.3 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-[4-(5-ethylthiophen-3-yl)-2,3-difluorophenyl]im-
idazolidin-2-one (Compound 61)
##STR00342##
[0429] The
1-(1H-benzimidazol-5-yl)-5-[4-(5-ethylthiophen-3-yl)-2,3-difluo-
rophenyl]-imidazolidin-2-one (Compound 61) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and compound 203d. The
experimental procedures were the same as the synthesis of Compound
1. The product (Compound 61) was obtained as a white solid at a
yield of 70%. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 1.28 (t,
3H, J=7.6 Hz), 2.83 (q, 2H, J=7.6 Hz), 3.44 (dd, 1H, J=6.4, 9.2
Hz), 4.05 (dd, 1H, J=9.2, 9.6 Hz), 5.82 (dd, 1H, J=6.4, 9.6 Hz),
7.05 (s, 1H), 7.15-7.19 (m, 1H), 7.26-7.34 (m, 2H), 7.41 (s, 1H),
7.50 (d, 1H, J=8.8 Hz), 7.60 (s, 1H), 8.08 (s, 1H); LC/MS (ESI)
m/z: 425.1 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{2,3-difluoro-4-[5-(methoxymethyl)thiophen-3-yl-
]phenyl}imidazolidin-2-one (Compound 62)
##STR00343##
[0431] The
1-(1H-benzimidazol-5-yl)-5-{2,3-difluoro-4-[5-(methoxymethyl)th-
iophen-3-yl]phenyl}imidazolidin-2-one (Compound 62) was prepared
from the cycloaddition of 1,1'-carbonyl diimidazole and compound
203e. The experimental procedures were the same as the synthesis of
Compound 1. The product (Compound 62) was obtained as a white solid
at a yield of 76%. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 3.34
(s, 3H), 3.45 (dd, 1H, J=6.8, 9.2 Hz), 4.05 (dd, 1H, J=9.2, 9.2
Hz), 4.59 (s, 2H), 5.82 (dd, 1H, J=6.4, 9.2 Hz), 7.17-7.21 (m, 1H),
7.28-7.34 (m, 3H), 7.50 (d, 1H, J=8.4 Hz), 7.60 (s, 1H), 7.62 (s,
1H), 8.08 (s, 1H); LC/MS (ESI) m/z: 441.3 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{4-[5-(ethoxymethyl)thiophen-3-yl]-2,3-difluoro-
phenyl}imidazolidin-2-one (Compound 63)
##STR00344##
[0433] The
1-(1H-benzimidazol-5-yl)-5-{4-[5-(ethoxymethyl)thiophen-3-yl]-2-
,3-difluorophenyl}imidazolidin-2-one (Compound 63) was prepared
from the cycloaddition of 1,1'-carbonyl diimidazole and compound
203f. The experimental procedures were the same as the synthesis of
Compound 1. The product (Compound 63) was obtained as a white solid
at a yield of 72%. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 1.19
(t, 3H, J=7.2 Hz), 3.45 (dd, 1H, J=6.4, 9.2 Hz), 3.54 (q, 2H, J=7.2
Hz), 4.05 (dd, 1H, J=9.2, 9.6 Hz), 4.63 (s, 2H), 5.83 (dd, 1H,
J=6.4, 9.6 Hz), 7.17-7.20 (m, 1H), 7.26-7.34 (m, 3H), 7.50 (d, 1H,
J=8.4 Hz), 7.61 (m, 2H), 8.08 (s, 1H); LC/MS (ESI) m/z: 455.3
[M+H].sup.+.
methyl
4-{4-[3-(1H-benzimidazol-5-yl)-2-oxoimidazolidin-4-yl]-2,3-difluoro-
phenyl}thiophene-2-carboxylate (Compound 64)
##STR00345##
[0435] The methyl
4-{4-[3-(1H-benzimidazol-5-yl)-2-oxoimidazolidin-4-yl]-2,3-difluorophenyl-
}thiophene-2-carboxylate (Compound 64) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and compound 203g. The
experimental procedures were the same as the synthesis of Compound
1. The product (Compound 64) was obtained as a white solid at a
yield of 75%. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 3.16-3.29
(m, 1H), 3.81 (s, 3H), 3.94 (dd, 1H, J=9.0, 9.3 Hz), 5.84 (dd, 1H,
J=5.4, 9.3 Hz), 7.11 (s, 1H), 7.17 (dd, 1H, J=6.9, 7.5 Hz), 7.30
(br s, 1H), 7.43-7.54 (m, 2H), 7.61 (s, 1H), 8.06-8.10 (m, 1H),
8.22 (s, 1H), 8.23 (s, 1H), 12.29 (br s, 1H); LC/MS (ESI) m/z:
455.1 [M+H]+.
1-(1H-benzimidazol-5-yl)-5-[2,3-difluoro-4-(thiophen-3-yl)phenyl]imidazoli-
din-2-one (Compound 65)
##STR00346##
[0437] The
1-(1H-benzimidazol-5-yl)-5-[2,3-difluoro-4-(thiophen-3-yl)pheny-
l]imidazolidin-2-one (Compound 65) was prepared from the
cycloaddition of 1,1'-carbonyl diimidazole and compound 203h. The
experimental procedures were the same as the synthesis of Compound
1. The product (Compound 65) was obtained as a white solid at a
yield of 79%. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 3.45 (dd,
1H, J=6.8, 9.2 Hz), 4.06 (dd, 1H, J=9.2, 9.6 Hz), 5.83 (dd, 1H,
J=6.8, 9.6 Hz), 7.20 (m, 1H), 7.31-7.36 (m, 3H), 7.44-7.52 (m, 2H),
7.61 (s, 1H), 7.66 (s, 1H), 8.08 (s, 1H); LC/MS (ESI) m/z: 397.1
[M+H].sup.+.
4-{4-[3-(1H-benzimidazol-5-yl)-2-oxoimidazolidin-4-yl]-2,3-difluorophenyl}-
thiophene-2-carboxylic acid (Compound 66)
##STR00347##
[0439] To the solution of the compound 64 (0.45 g, 1.0 mmol) in
methanol (10 mL), potassium hydroxide (0.07 g, 1.2 mmol) was added.
The reaction mixture was stirred at 60.degree. C. for 1.5 hours and
then cooled to room temperature. The reaction mixture was
neutralized by 1N HCl.sub.(aq) to pH 7. After removing the solvent,
the crude residue was purified by reverse phase column
chromatography on C-18 silica gel using methanol/H.sub.2O (1/1) as
eluent to give the product 66 as a white solid at a yield of 81%.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.26 (dd, 1H, J=5.6,
9.2 Hz), 3.92 (dd, 1H, J=9.2, 9.2 Hz), 4.18 (br s, 1H), 5.80 (dd,
1H, J=5.6, 9.2 Hz), 7.12-7.15 (m, 2H), 7.29 (br s, 1H), 7.40-7.46
(m, 2H), 7.52 (s, 1H), 7.61 (s, 1H), 7.67 (s, 1H), 8.09 (s, 1H);
LC/MS (ESI) m/z: 441.0 [M+H].sup.+.
1-(1H-benzimidazol-5-yl)-5-{2,3-difluoro-4-[5-(hydroxymethyl)thiophen-3-yl-
]phenyl}imidazolidin-2-one (Compound 67)
##STR00348##
[0441] A solution of compound 64 (0.45 g, 1.0 mmol) in dry THF (5
mL) was added dropwise to a refluxing, magnetically stirring slurry
of LAH (1.5 mmol) in dry THF (7.5 mL). The reaction mixture was
held at reflux for 3 hours, terminated by dropwise addition of 1 mL
saturated MgSO.sub.4 solution and filtered by Celite. The filtrate
was partitioned between ethyl acetate and water. The organic phases
were dried over MgSO.sub.4 and evaporated on a rotary evaporator.
The residue was purified by column chromatography on silica gel
using methanol/DCM (1/10) as eluent to give the product 67 as a
white solid at a yield of 92%.
Separation of Enantiomers of Compound 8
[0442] The chiral separation of Compound 8 was completed by HPLC
using CHIRALPAK IC. The isomer fractions were respectively
collected and the optical pure isomers (Compounds 9 and 10) were
thus obtained by removing the solvent under reduced pressure.
Results of this separation are shown below:
[0443] Column: CHIRALPAK IC (IC00CE-OL002),
[0444] Column size: 0.46 cm I.D..times.25 cm L,
[0445] Injection: 0.5 ul,
[0446] Mobile phase: 100% methanol,
[0447] Flow rate: 1.0 ml/min,
[0448] Detection: UV 214 nm,
[0449] Temperature: 35.degree. C.,
[0450] HPLC equipment: Shimadzu LC-20AD (CP-HPLC-06),
[0451] Retention E1 (Compound 9): 5.494 min,
[0452] Retention E2 (Compound 10): 6.379 min.
Separation of Enantiomers of Compound 13
[0453] The chiral separation of Compound 13 was completed by HPLC
using CHIRALPAK AD-H. The isomer fractions were respectively
collected and the optical pure isomers (Compounds 33 and 34) were
thus obtained by removing the solvent under reduced pressure.
Results of this separation are shown below:
[0454] Column: CHIRALPAK AD-H (ADH0CD-UE022),
[0455] Column size: 0.46 cm I.D..times.15 cm L,
[0456] Injection: 1.0 ul,
[0457] Mobile phase: Hexane/EtOH=60/40 (v/v),
[0458] Flow rate: 1.0 ml/min,
[0459] Detection: UV 214 nm,
[0460] Temperature: 35.degree. C.,
[0461] HPLC equipment: Shimadzu LC-20AT (CP-HPLC-09),
[0462] Retention E1 (Compound 33): 4.270 min,
[0463] Retention E2 (Compound 34): 5.679 min.
Separation of Enantiomers of Compound 16
[0464] The chiral separation of Compound 16 was completed by HPLC
using CHIRALPAK AD-H. The isomer fractions were respectively
collected and the optical pure isomers (Compounds 35 and 36) were
thus obtained by removing the solvent under reduced pressure.
Results of this separation are shown below:
[0465] Column: CHIRALPAK AD-H (ADH0CD-UE022),
[0466] Column size: 0.46 cm I.D..times.15 cm L,
[0467] Injection: 2.0 ul,
[0468] Mobile phase: Hexane/EtOH=70/30 (v/v),
[0469] Flow rate: 1.0 ml/min,
[0470] Detection: UV 214 nm,
[0471] Temperature: 35.degree. C.,
[0472] HPLC equipment: Shimadzu LC-20AD (CP-HPLC-08),
[0473] Retention E1 (Compound 35): 7.273 min,
[0474] Retention E2 (Compound 36): 9.232 min.
Separation of Enantiomers of Compound 25
[0475] The chiral separation of Compound 25 was completed by HPLC
using CHIRALPAK AD-H. The isomer fractions were respectively
collected and the optical pure isomers (Compounds 53 and 54) were
thus obtained by removing the solvent under reduced pressure.
Results of this separation are shown below:
[0476] Column: CHIRALPAK AD-H (ADH0CD-UE022),
[0477] Column size: 0.46 cm I.D..times.15 cm L,
[0478] Injection: 2.0 ul,
[0479] Mobile phase: Hexane/EtOH=70/30 (v/v),
[0480] Flow rate: 1.0 ml/min,
[0481] Detection: UV 214 nm,
[0482] Temperature: 35.degree. C.,
[0483] HPLC equipment: Shimadzu LC-20AD (CP-HPLC-08),
[0484] Retention E1 (Compound 53): 2.166 min,
[0485] Retention E2 (Compound 54): 2.767 min.
Separation of Enantiomers of Compound 28
[0486] The chiral separation of Compound 28 was completed by HPLC
using CHIRALPAK AD-H. The isomer fractions were respectively
collected and the optical pure isomers (Compounds 55 and 56) were
thus obtained by removing the solvent under reduced pressure.
Results of this separation are shown below:
[0487] Column: CHIRALPAK AD-H (ADH0CD-UE022),
[0488] Column size: 0.46 cm I.D..times.15 cm L,
[0489] Injection: 2.0 ul,
[0490] Mobile phase: Hexane/EtOH=70/30 (v/v),
[0491] Flow rate: 1.0 ml/min,
[0492] Detection: UV 214 nm,
[0493] Temperature: 35.degree. C.,
[0494] HPLC equipment: Shimadzu LC-20AD (CP-HPLC-08),
[0495] Retention E1 (Compound 55): 3.827 min,
[0496] Retention E2 (Compound 56): 7.914 min.
Example 2: In Vitro Activity Screening of Compounds
QC Activity Assay
[0497] An enzymatic activity assay of QC was conducted at
25.degree. C. using a fluorescent substrate, i.e., L-glutaminyl
2-naphthylamide (Gln-.beta.NA). See Huang et al., Biochem. J. 2008,
411, 181-190. A 100 .mu.l reaction mixture was prepared. It
contained 300 .mu.M of fluorogenic substrate, .about.0.2 units of
auxiliary enzyme human pyroglutamyl aminopeptidase I (PAP I) (in
which one unit is defined as the amount of human PAP I needed to
hydrolyzes 1 .mu.mol of pGlu-3NA per minute under the same assay
condition), and an appropriately diluted aliquot of recombinant QC
in 50 mM of Tris-HCl at pH 8.0. Excitation and emission wavelengths
were set at 320 and 410 nm, respectively. The reaction was
initiated by the addition of QC. The enzymatic activity of QC was
determined from the amount of released (3NA and was calculated
using a standard curve for (3NA under the same assay conditions.
Measurements were made using a Synergy H4 microplate reader
(BioTek, Winooski, Vt., USA).
Enzyme Kinetic Assay
[0498] Kinetic constants were determined at pH 8.0 and 25.degree.
C. using Gln-.beta.NA as the substrate. Also see Huang et al.,
Biochem. J. 2008, 411, 181-190. The reaction was initiated by
adding QC to the 100 al reaction mixture described above. The
initial rate was measured with less than 10% substrate depletion
for the first 2-12 minutes. Since a weak substrate inhibition was
observed, kinetic parameters K.sub.m, V, and K.sub.i were evaluated
by fitting an equation, i.e.,
v.sub.0=V.sub.max[S]/(K.sub.m+[S]+[S]2/K.sub.i), to initial
velocity data by nonlinear regression using a KaleidaGraph software
(Synergy Software, Reading, Pa., USA), where v.sub.0 is an initial
velocity, V.sub.max is an limiting rate, [S] is a substrate
concentration, K.sub.m is a Michaelis constant, and K.sub.i is an
inhibition constant.
QC Inhibition Assay
[0499] An inhibition activity assay of QC inhibitors was conducted.
See Huang et al., J. Biol. Chem. 2011, 286, 12439-12449. A reaction
mixture containing 300 .mu.M of Gln-.beta.NA and .about.0.2 units
of human PAP I was prepared. QC was first incubated with an
inhibitor at 25.degree. C. for 30 minutes and the enzyme-inhibitor
mixture was then added to the reaction mixture to initiate the
cyclization reaction. An IC.sub.50 value was obtained by fitting an
initial reaction rate versus an inhibitor concentration using
KaleidaGraph. A K.sub.i value of the inhibitor was calculated
according to an equation IC.sub.50=K.sub.i(1+[S]/K.sub.m). See
Segel, Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium
and Steady-State Enzyme Systems, pp. 100-118. New York: John Wiley
& Sons, 1993. In this equation, [S] is a substrate (i.e.,
Gln-.beta.NA) concentration and K.sub.m is a Michaelis-Menten
constant. The lower the K.sub.i value, the higher the inhibitor's
QC inhibition rate.
[0500] The K.sub.i values of Compounds 1-29, 33-57, and 59-65,
obtained from the inhibition assay set forth above, are shown in
Table 2 below.
TABLE-US-00002 TABLE 2 Compound K.sub.i (.mu.M) 1 0.053 2 0.100 3
0.348 7 0.021 8 0.049 9 0.016 10 0.964 11 0.100 12 0.132 13 0.124
14 0.106 15 0.076 16 0.112 17 0.151 18 0.134 19 0.058 20 0.057 21
0.036 22 0.156 23 0.124 24 0.101 25 0.071 26 0.114 27 0.066 28
0.039 29 0.072 33 0.736 34 0.069 35 2.053 36 0.032 37 0.018 38
0.004 39 0.004 40 0.009 41 0.012 42 0.005 43 0.008 44 0.010 45
0.004 46 0.008 47 0.006 48 0.010 49 0.010 50 0.013 51 0.024 52
0.397 53 3.417 54 0.023 55 1.592 56 0.007 57 0.087 59 0.019 60
0.007 61 0.016 62 0.006 63 0.011 64 0.013 65 0.020
[0501] As shown in this table, Compounds 1-29, 33-57, and 59-65 all
have K.sub.i values within the nano molar range. Note that a low
K.sub.i value indicates a high QC inhibition rate. Clearly, these
compounds possess superior inhibition potency against QC.
[0502] Inhibition of QC has been reported to diminish aggregation
of A.beta. and HTT in cultured macrophage cells and in Drosophila
and mouse models. Thus, Compounds 1-29, 33-57, and 59-65, as potent
QC inhibitors, are drug candidates for treating AD or HD.
Example 3: In Vivo Activity of Compounds
[0503] Compound 37 showed strong potency (K.sub.i=0.018 .mu.M) in
inhibiting QC and a desired pharmacokinetic property (F %=11) in
mice (F % being the fraction of an oral administered drug that
reaches systemic circulation). The compound was therefore selected
for further animal studies in a transgenic mouse model using APP/PS
1 mice (Jackson Lab, ME). See Schilling et al., Nat. Med. 2008, 14,
1106-1111 and Li et al., J. Med. Chem. 2017, 60, 6664-6677. APP/PS1
mice are double transgenic mice expressing a chimeric mouse/human
amyloid precursor protein (Mo/HuAPP695swe) and a mutant human
presenilin 1 (PS 1-dE9), both directed to CNS neurons. These two
mutations are associated with early-onset Alzheimer's disease. In
the animal studies, 4-month-old APP/PS 1 mice were housed at a 12
hour day/12 hour night cycle with free access to water and food.
Compound 37 was orally administered to the APP/PS 1 mice for 3.5
months to determine its in vivo activity. The cognitive function
and brain pathology of each mouse were analyzed after the
administration. The resultant analytical data exhibited depletion
of A.beta. deposits in brain tissues of the APP/PS 1 mice.
[0504] The same in vivo assay was performed on Compound 28, which
showed that this compound had high inhibitory activity
(K.sub.i=0.039 .mu.M) and a superior pharmacokinetic property with
desired oral bioavailability (F %=25) in APP/PS 1 mice.
[0505] The above two assays demonstrate both the potency and the
efficacy of Compounds 28 and 37 as QC inhibitors for treating
AD.
Other Embodiments
[0506] All of the features disclosed in this specification may be
combined in any combination. Each feature disclosed in this
specification may be replaced by an alternative feature serving the
same, equivalent, or similar purpose. Thus, unless expressly stated
otherwise, each feature disclosed herein is only an example of a
series of equivalent or similar features.
[0507] From the above description, one skilled in the art can
easily ascertain the essential characteristics of the present
invention and, without departing from the spirit and scope thereof,
can make various changes and modifications of the invention to
adapt it to various usages and conditions. Thus, other embodiments
are also within the scope of the following claims.
* * * * *